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Abstract
The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific
opinion on Quillaia extract (E 999) when used as a food additive and the evaluation of the safety of its
proposed extension of use as a food additive in flavourings. The Scientific Committee for Food (SCF) in
1978 established an acceptable daily intake (ADI) of 0–5 mg spray-dried extract/kg body weight (bw) per
day for E 999. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) established in its latest
evaluation a group ADI of 0–1 mg/kg bw per day, expressed as quillaia saponins, for Quillaia extract for
Type 1 and Type 2. The Panel considered it likely that intact Quillaia extract saponins are absorbed to a
low extent, are hydrolysed in the gastrointestinal (GI) tract and that the aglycone is absorbed only to a
limited extent. The Panel considered that the genotoxicity data available did not indicate a concern for
genotoxicity. Taking into account the available toxicological database, various no observed adverse effect
levels (NOAELs) relevant for the derivation of an ADI were identified. The Panel considered that the
2-year study in rats was the most robust and that the NOAEL of 1,500 mg Quillaia extract/kg bw per day
could be used to derive the ADI for E 999. Considering that the adverse effects reported were due to the
presence of saponins in the extract, that saponins were present in Quillaia extract Type 1 (around 20%)
and using an uncertainty factor of 100, the Panel derived a ADI of 3 mg saponins/kg bw per day for
E 999. None of the exposure estimates for the different population groups of the refined brand-loyal
scenario exceeded the ADI of 3 mg saponins/kg bw per day. The proposed extension of use also would
not result in an exceedance of this ADI for the refined scenario. The Panel proposed some
recommendations for the European Commission to consider, in particular revising the EU specifications
for E 999 in order to differentiate the extracts of Quillaia according to the saponins content and to include
other parameters to better characterise the food additive.
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Summary
Quillaia extract (E 999) is obtained by aqueous extraction of the milled inner bark or wood of
Quillaja saponaria Molina, or other Quillaja species, trees of the family Rosaceae. It contains a number
of triterpenoid saponins consisting of glycosides of quillaic acid. Sugars – including glucose, galactose,
arabinose, xylose, and rhamnose – are also present, along with tannin, calcium oxalate and other
minor components.
Quillaia extract (E 999) was evaluated by the Scientific Committee for Food (SCF) in 1978 who
established an acceptable daily intake (ADI) of 0–5 mg spray-dried extract/kg body weight (bw) per
day based on two long-term studies in rats and mice.
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) established in its latest evaluation
a group ADI of 0–1 mg/kg bw per day, expressed as quillaia saponins, for Quillaia extract for Type 1
and Type 2.
The Panel noted that existing EU specifications for E 999 do not describe any range for saponins
content in the food additive. The JECFA specifications, however, differentiate two types of Quillaia
extracts, Type 1 and Type 2, containing a different percentage of saponins and other parameters. The
Panel considered that similar differentiation of the extracts of Quillaia should be presented in the EU
specifications, including the percentage range for saponins, polyphenols (including tannins), protein,
polysaccharides including fibre, reducing sugars, a maximum limit for calcium oxalate as well as
microbiological specifications.
The Panel assumed that the test materials used in toxicological studies described as Quillaia extract
approximated to Quillaia extract Type 1 as described in JECFA. However, from the information
available, the Panel could not ascertain the comparability of test materials between different studies.
The Panel noted that the material used in the toxicity studies may be compliant with the current EU
specifications; however, it is only poorly characterised.
The Panel considered that the extent and the quality of the available data on the absorption,
distribution, metabolism, excretion (ADME) of Quillaia extract saponins were very limited and that no
conclusions could be drawn based on studies with Quillaia extracts. The Panel, therefore, considered
the available data on gastrointestinal (GI) metabolism and ADME for structurally similar saponins.
Based on read-across from these data, the Panel presumed that Quillaia extract saponins share a
similar fate. Thus, the Panel considered it likely that intact Quillaia extract saponins are absorbed to a
low extent; are hydrolysed in the GI tract and that the aglycone is absorbed only to a limited extent.
The Panel considered that, from the limited data available, the acute toxicity for Quillaia extract
was low.
The Panel noted a no observed adverse effect level (NOAEL) of 0.6% Quillaia extract
(approximately 400 mg/kg bw per day) from a 13-week study in rats in which relative organ weights
were changed at the next higher dose of 1,200 mg/kg bw per day. The Panel also noted that no
histopathological changes were observed at any dose.
The Panel considered that the data on the chemical composition of the mixture and the
genotoxicity data available did not indicate a concern for genotoxicity.
The Panel identified a NOAEL of 750 mg Quillaia extract/kg bw per day from a 84-week study in
mice and a NOAEL of 1,500 mg Quillaia extract/kg bw per day, the highest dose tested, from the 2-
year study in rats. There was no indication for carcinogenicity. In the mouse study, slightly lower body
weight gain and some organ weight changes in the high-dose group of 2,250 mg/kg bw per day
Quillaia extract were reported but there were no histopathological changes.
No reproductive or developmental toxicity data were available to the Panel. However, in a chronic
study in rats, no adverse effects were observed in the reproductive organs.
The Panel considered the gut epithelium - as a site of contact – a potential target for any effects of
Quillaia extract. The Panel therefore focussed attention on any GI effects in the biological and
toxicological studies. The Panel considered that although exposure to Quillaia extract resulted in
changes in GI organ weights in several studies relevant to its use as a food additive, these changes
were not accompanied by any consistent treatment- and/or dose-related histopathological changes.
Taking into account the available toxicological database, the Panel noted that various NOAELs
relevant for the derivation of an ADI were identified:
• a NOAEL of 400 mg Quillaia extract /kg bw per day in a 13-week study in rats,
• a NOAEL of 750 mg Quillaia extract/ kg bw per day in an 84-week study in mice,
• a NOAEL of 1,500 mg Quillaia extract/kg bw per day (the highest dose tested) in a 2-year
study in rats.
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Overall, the Panel considered that the 2-year study in rats was the most robust and that the NOAEL of
1,500 mg Quillaia extract/kg bw per day could be used to derive the ADI for Quillaia extract (E 999).
Considering that the adverse effects reported were due to the presence of saponins in the extract, that
saponins were present in Quillaia extract Type 1 at around 20% (conservative scenario since Quillaia
extract Type 1 may contain 20–26% of saponins) and using an uncertainty factor of 100, the
Panel derived a ADI of 3 mg saponins/kg bw per day for the food additive Quillaia extract (E 999).
Accordingly, the ADI for Quillaia extract (E 999) of 5 mg spray-dried extract/kg bw per day is withdrawn.
Quillaia extract (E 999) is currently authorised as a food additive for use in two food categories.
The requested use as a food additive in flavourings relates to five other food categories. The exposure
to this food additive was estimated based on maximum permitted levels (MPLs) and use levels, both
for its current uses only and its current uses and intended extension of uses, based on the proposed
maximum levels in final foods by the applicant (Section 3.4.1). As described in Section 3.4.1, overall
the Panel estimated that the exposure to Quillaia extract (E 999) was overestimated in all scenarios.
The Panel noted that MPLs are expressed as anhydrous extract in Annex II to Regulation
No 1333/2008. Therefore, exposure to Quillaia extract (E 999) was expressed in mg anhydrous extract
of Quillaia extracts (E 999)/kg bw per day. Considering that the ADI is expressed in mg saponins,
exposure was also converted to saponins, assuming that Quillaia extract (E 999) contains 70%
saponins (Type 2) for the current authorised use levels and as proposed by the applicant, 20% saponins.
Therefore, exposure using the current MPLs (regulatory maximum level exposure assessment scenario)
ranged between < 0.1 mg saponins/kg bw per day at the mean and up to 6.7 mg saponins/kg bw per day
at the 95th percentile. Using the refined exposure assessment scenario including the proposed extension
of use, exposure ranged between < 0.1 mg saponins/kg bw per day at the mean and up to 0.7 mg
saponins/kg bw per day at the 95th percentile.
To assess possible health risks related to the current use of Quillaia extract (E 999), the
Panel selected the brand-loyal scenario, as the additive is used in FC 14.1.4 Flavoured drinks. None of
the exposure estimates for the different population groups of the brand-loyal scenario exceeded the
ADI of 3 mg saponins/kg bw per day. Also, the proposed extension of use as a food additive in
flavourings did not result in an exceedance of this ADI at the refined exposure assessment scenario.
The applicant proposed the addition of sodium benzoate (E 211) to Annex III of Regulation (EC) No
1333/2008 as a preservative for use in liquid formulations of Quillaia extracts (E 999). The Panel noted
that exposure to sodium benzoate (E 212) at the levels proposed to be used in the preparation of
Quillaia extract (E 999) would add at the maximum 0.13% to the exposure to benzoic acid–benzoates
(E 210–213) as food additives, considering their use according to Annex II to Regulation No 1333/2008
and additional exposure from food categories which may contain benzoic acid–benzoates due to carry-
over, for which an exceedance of the ADI of 5 mg/kg bw per day, expressed as benzoic acid, was
observed in the non-brand-loyal scenario for toddlers and children (EFSA ANS Panel, 2016).
The Panel recommended that the European Commission considers:
• Revising the EU specifications for Quillaia extracts (E 999) in order to differentiate extracts of
Quillaia according to their saponins content (including a description of the principle of the
method of analysis to quantify the content of saponins in line with the JECFA specifications),
i.e. Type 1 and Type 2.
• Revising the EU specifications to include the percentage range for polyphenols (including
tannins), protein, polysaccharides including fibre, reducing sugars, a maximum limit for calcium
oxalate as well as microbiological specifications.
• Lowering the current limits for toxic elements (arsenic, lead and mercury) in the EU
specifications for Quillaia extracts (E 999) in order to ensure that the food additive will not be
a significant source of exposure to these toxic elements in food.
• Revising the maximum use levels for Quillaia extracts (E 999) established in Regulation (EC)
No 1333/2008 to be expressed on saponin content.
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1. Introduction
The present opinion document deals with the re-evaluation of Quillaia extract (E 999) when used as
a food additive and the evaluation of the safety of its proposed extension of use as a food additive in
flavourings.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background and Terms of Reference to the re-evaluation of the food
additive Quillaia extract (E 999)
Background
Regulation (EC) No 1333/20081 of the European Parliament and of the Council on food additives
requires that food additives are subject to a safety evaluation by the European Food Safety Authority
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food
additives must be kept under continuous observation and must be re-evaluated by EFSA.
For this purpose, a programme for the re-evaluation of food additives that were already permitted in
the European Union before 20 January 2009 has been set up under the Regulation (EU) No 257/2010.2
This Regulation also foresees that food additives are re-evaluated whenever necessary in light of
changing conditions of use and new scientific information. For efficiency and practical purposes, the re-
evaluation should, as far as possible, be conducted by group of food additives according to the main
functional class to which they belong.
The order of priorities for the re-evaluation of the currently approved food additives should be set on
the basis of the following criteria: the time since the last evaluation of a food additive by the Scientific
Committee on Food (SCF) or by EFSA, the availability of new scientific evidence, the extent of use of a
food additive in food and the human exposure to the food additive taking also into account the outcome
of the Report from the Commission on Dietary Food Additive Intake in the EU3 of 2001. The report “Food
additives in Europe 20004” submitted by the Nordic Council of Ministers to the Commission, provides
additional information for the prioritisation of additives for re-evaluation. As colours were among the first
additives to be evaluated, these food additives should be re-evaluated with a highest priority.
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised
food additives. However, as a result of adoption of Regulation (EU) 257/2010 the 2003 Terms of
References are replaced by those below.
Terms of Reference
The Commission asks the European Food Safety Authority to re-evaluate the safety of food
additives already permitted in the Union before 2009 and to issue scientific opinions on these
additives, taking especially into account the priorities, procedures and deadlines that are enshrined in
the Regulation (EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of
approved food additives in accordance with the Regulation (EC) No 1333/2008 of the European
Parliament and of the Council on food additives.
1.1.2. Background and Terms of Reference to the evaluation of the safety of the
extension of use of Quillaia extract (E 999)
Background
An application has been introduced for the authorisation of Quillaia extract (E 999) as a food
additive in flavourings. This food additive (emulsifier, foaming agent) is intended to be added at
different maximum levels [when added at the maximum proposed levels to flavourings, would give rise
to maximum use levels] in the following food categories:
1 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16–33.
2 Commission Regulation (EU) No 257/2010 of 25 march 2010 setting up a programme for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, p. 19–27.
3 COM(2001) 542 final.
4 Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nordic Council of
Ministers, TemaNord 2002, 560.
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5.2 Other confectionery including breath refreshening microsweets 18
5.3 Chewing gum 9
12.5 Soups and broths 10
14.1.5 Coffee, tea, herbal and fruit infusions, chicory; tea, herbal and fruit infusion and
chicory extracts; tea, plant, fruit and cereal preparations for infusions, as well as mixes
and instant mixes of these products
6
15.1 Potato-, cereal-, flour- or starch-based snacks 1
Quillaia extract (E 999) is currently an authorised food additive in the European Union under Annex
II of Regulation (EC) No 1333/2008 for use in the food categories 14.1.4 Flavoured drinks and 14.2.3
Cider and perry, both at a maximum level of 200 mg/L.
The Scientific Committee for Food (SCF) assessed the information on the safety in use of Quillaia
extract (E 999) as food additive (emulsifier, foaming agent) in soft drinks, and expressed its opinion on
a report on Emulsifiers, Stabilizers, Thickeners and Gelling Agents dated from December 1978.5 The
same authority considered in detail the composition of that product, its pharmacological properties, the
source of the material and the results of two long-term studies in the mouse and rat. For the spray-dried
extract the Committee established an ADI of 5 mg/kg bw per day.
In addition, also the Joint FAO/WHO Expert Committee on Food Additives (JECFA) performed a safety
evaluation of Quillaia extract in 20026 setting a ‘temporary’ ADI of 5 mg/kg bw per day, and in 20057
establishing a group ADI of 1 mg/kg bw per day for Type 1 and Type 2 extract expressed as quillaia
saponins. The previously established ADI of 5 mg/kg bw per day for Type 1 extract was withdrawn.
Taking into account the outcome of the SCF and JECFA’s assessments, the European Commission
asks the European Food Safety Authority to consider the information submitted by the applicant and,
in particular, to clarify its impact on the established ADI as well as to carry out a refined exposure
assessment of Quillaia extract (E 999).
Terms of Reference
The European Commission asks the European Food Safety Authority to provide a scientific opinion on
the safety of the proposed extension of use of Quillaia extract (E 999) as a food additive in ‘flavourings’
in the food categories specified in the dossier, in accordance with Regulation (EC) No 1331/2008
establishing a common authorisation procedure for food additives, food enzymes and food flavourings.
Interpretation of Terms of Reference
According to the applicant, as also mentioned in the JECFA specifications (JECFA, 2006c, 2014),
sodium benzoate is used in liquid preparations of Quillaia extracts (E 999).
Currently, according to Annex III Part 2 ‘food additives other than carriers in food additives’ of the
Regulation (EC) No 1333/2008, sodium benzoate can only be used in colour preparations. The applicant
proposed the addition of sodium benzoate (E 211) to Annex III of Regulation (EC) No 1333/2008 as a
preservative for use in liquid formulations of Quillaia extracts (E 999) in line with the JECFA specifications
(Documentation provided to EFSA n. 6).
Therefore, the Panel considered additional exposure to sodium benzoate (E 211) from the current
authorised uses and the requested extension of use of Quillaia extracts (E 999).
1.2. Information on existing authorisations and evaluations
Quillaia extract (E 999) is authorised as a food additive in the EU in accordance with Annex II to
Regulation (EC) No 1333/2008 on food additives and specifications have been defined in the
Commission Regulation (EU) No 231/20128.
In the EU, Quillaia extract (E 999) was evaluated by the SCF in 1978 (SCF, 1978) who established




8 Commission Regulation (EU) No 231/2012 of 9 march 2012 laying down specifications for food additives listed in Annexes II
and III to Regulation (EC) no 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p. 1.
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opinion, the SCF specified that the toxicological evaluation considered for its opinion was carried out
on a natural extract of Quillaia bark as specified in the British Pharmacopoeia 1973 (more information
on the British Pharmacopoeia in 1973 available in Appendix A). The two major saponins present in
Quillaia extract, as described in the SCF opinion, were quillaia sapogenin which has a triterpenoid
structure and quillaic acid; these saponins were considered by the SCF to constitute about 10% of the
extract. The ADI was based on two long-term studies in rats and mice [cited by the SCF as
unpublished studies by Butterworth (1977a,b), later published as Phillips et al. (1979) and Drake et al.
(1982) respectively].
Quillaia extract (E 999) was evaluated by JECFA in 1982, 1986, 2002, 2004 and 2006 (JECFA, 1982a,
b, 1986, 2002a,b, 2004, 2005, 2006a,b). JECFA currently defines two types of Quillaia extract: Type 1
extract, INS No 999(i), obtained by means of aqueous extraction and characterised by a saponins
content in the range of 20–26% and Type 2 extract, INS No 999(ii), prepared by ultrafiltration of Type 1
extract and with a saponins content of 65–90%. The latest evaluation by JECFA established a group ADI
of 0–1 mg/kg bw per day for Type 1 and Type 2 extracts, expressed as quillaia saponins.
Quillaja saponaria Molina is included in the Compendium of botanicals reported to contain naturally
occurring substances of possible concern for human health when used in food and food supplements
(EFSA, online). The chemicals of interest for Quillaja saponaria Molina, as listed in the compendium,
are triterpenoid saponins (quillaja saponins) and calcium oxalate (11%).
The Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA)
evaluated quillaia saponins as pharmacologically-active substances and concluded that there was no
need to establish a maximum residue level (MRL) for these substances in food of animal origin (EMA,
1996).
Quillaja saponaria ext (CAS 68990-67-0) has been registered under the REACH Regulation 1907/20069
(ECHA, online).
The FSANZ established a group ADI of 0–1 mg quillaia saponins/kg bw to permit the use of Type 1
(unpurified) and Type 2 (saponin enriched) extracts (FSANZ, 2013).
2. Data and methodologies
2.1. Data
The Panel on Food Additives and Flavourings (FAF) was not provided with a newly submitted
dossier for the re-evaluation of Quillaia extract (E 999) as a food additive. EFSA launched a public call
for data10 to collect information from interested parties.
An applicant has submitted a dossier in support of the application for the extension of use of
Quillaia extract (E 999) as a food additive in flavourings which is also addressed in this opinion (see
‘Documentation provided to EFSA n. 1’).
Additional information was submitted by the applicant (jointly with other interested parties) to EFSA
during the assessment process, in response to requests from EFSA sent on 10 March 2015, on 30
September 2015, on 3 June 2016, on 13 June 2018 and on 29 October 2018 (see ‘Documentation
provided to EFSA n. 6–10’).
The Panel based its assessment on information submitted to EFSA following the public calls for
data, information from previous evaluations and additional available literature up to December 2018.
Attempts were made to retrieve relevant original study reports on which previous evaluations or
reviews were based, however these were not always available to the Panel.
Food consumption data used to estimate dietary exposure to Quillaia extract (E 999) were derived
from the EFSA Comprehensive European Food Consumption Database (Comprehensive Database11).
The Mintel’s Global New Products Database (GNPD) was used to verify the use of Quillaia extract
(E 999) in food and beverage products and food supplements within the EU’s market. The Mintel’s
GNPD is an online database that contains the compulsory ingredient information present on the label
of numerous products.
9 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). OJ L 396, 30.12.2006.
10 Call for scientific data on food additives permitted in the EU and belonging to the functional classes of emulsifiers, stabilisers
and gelling agents. Published: 22 November 2009. Available from: http://www.efsa.europa.eu/en/dataclosed/call/ans091123
11 Available online: http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm
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2.2. Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency with regard to scientific aspects of risk assessment (EFSA Scientific Committee, 2009)
and following the relevant existing Guidance documents from the EFSA Scientific Committee.
The FAF Panel assessed the safety of Quillaia extract (E 999) as a food additive in line with the
principles laid down in Regulation (EU) 257/2010 and in the relevant guidance documents: Guidance
on submission for food additive evaluations by the SCF (2001) and taking into consideration the
Guidance for submission for food additive evaluations in 2012 (EFSA ANS Panel, 2012).
When the test substance was administered in the feed or in the drinking water, but doses were not
explicitly reported by the authors as mg/kg bw per day based on actual feed or water consumption,
the daily intake was calculated by the Panel using the relevant default values as indicated in the EFSA
Scientific Committee Guidance document (EFSA Scientific Committee, 2012) for studies in rodents or,
in the case of other animal species, by JECFA (2000). In these cases, the daily intake was expressed
as equivalent.
Dietary exposure to Quillaia extract (E 999) from its use as a food additive was estimated
combining food consumption data available within the EFSA Comprehensive European Food
Consumption Database with maximum permitted levels according to Annex II to Regulation (EC) No
1333/2008 and reported use levels submitted to EFSA following a call for data. The exposure was
estimated according to different scenarios (see Section 3.4.1). Uncertainties in the exposure
assessment were identified and discussed.
3. Assessment
3.1. Technical data
3.1.1. Identity of the substance
According to Commission Regulation (EU) No 231/2012, Quillaia extract (E 999) is obtained by
aqueous extraction of Quillaia saponaria Molina, or other Quillaia species, trees of the family Rosaceae.
It contains a number of triterpenoid saponins consisting of glycosides of quillaic acid. Sugars –
including glucose, galactose, arabinose, xylose and rhamnose – are also present, along with tannin,
calcium oxalate and other minor components. No chemical name, EC/EINECS Number, chemical
formula or molecular weight are provided in the EU specifications.
Synonyms: Soapbark extract; Quillay bark extract; Panama bark extract; Quillai extract; Murillo bark
extract; China bark extract.
Quillaja saponaria extract is registered with EC No 273-620-4 and CAS No 68990-67-0, the same CAS
number cited for Quillaia extract Type 1 and Type 2 in the JECFA specifications (JECFA, 2006c, 2014).
The following trade names have been reported by the interested parties (Documentation provided
to EFSA n. 6) for Quillaia extract (Type 1): FoamationTM Q200 (Ingredion), UPTAIATM (Naturex), Saponin
5012/Saponin Powder HG (Kerry) and for Quillaia extract (Type 2): Q-NaturaleTM (Ingredion); SAPNOVTM
(Naturex).
The general structural formulae of quillaia saponins is shown in Figure 1.
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3.1.2. Specifications
The specifications for Quillaia extract as defined in the Commission Regulation (EU) No 231/2012
and by JECFA (2006c, 2014) are listed in Table 1.
Gal: D-galactose; GlcA: D-glucoronic acid; Rha: D-rhamnose; Xyl: D-xylose; Ara: D-arabinose; Rhap: D-rhamnopyranose;
Xylp: D-xylopyranose; Apif: apiofuranose.
Figure 1: General structure of quillaia saponins (quillaic acid as aglycone (sapogenin) component)
(G€ucl€u-Ust€undag and Mazza, 2007)
Table 1: Specifications for Quillaia extract (E 999) according to Commission Regulation (EU) No
231/2012 and JECFA (2006c, 2014)
Commission Regulation
(EU) No 231/2012
JECFA (2006c) Type 1
[INS No 999(i)]
JECFA (2014) Type 2
[INS No 999(ii)]
Definition Quillaia extract is obtained
by aqueous extraction of
Quillaia saponaria Molina, or
other Quillaia species, trees
of the family Rosaceae. It
contains a number of
triterpenoid saponins
consisting of glycosides of
quillaic acid. Some sugars
including glucose, galactose,
arabinose, xylose, and
rhamnose are also present,
along with tannin, calcium
oxalate and other minor
components
Quillaia extract (Type 1) is
obtained by aqueous extraction
of the milled inner bark or of
the wood of pruned stems and
branches of Quillaja saponaria




glycosides of quillaic acid.
Polyphenols and tannins are
major components and some
sugars and calcium oxalate will
be present
Quillaia extract (Type 1) is
Quillaia extract (Type 2) is
obtained either by
chromatographic separation or
ultrafiltration of the aqueous
extraction of the milled inner
bark or of the wood of pruned





predominantly of glycosides of
quillaic acid. Polyphenols and
tannins are minor components.
Some sugars and calcium
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Commission Regulation
(EU) No 231/2012
JECFA (2006c) Type 1
[INS No 999(i)]
JECFA (2014) Type 2
[INS No 999(ii)]
available commercially as liquid
product or as spray-dried
powder that may contain
carriers such as lactose, maltitol
or maltodextrin. The liquid
product is usually preserved
with sodium benzoate or
ethanol
oxalate will also be present
Quillaia extract (Type 2) is
available commercially as a
liquid product or as a spray-
dried powder that may contain
carriers such as lactose, maltitol
or maltodextrin. The liquid
product is usually preserved
with sodium benzoate or
ethanol
CAS Number 68990-67-0
Formula weight Monomeric saponins range from ca. 1,800 to ca. 2,300,




Not less than 20% and not
more than 26% on the dried
basis
Not less than 65% and not
more than 90% on the dried
basis
Description Quillaia extract in the
powder form is light brown
with a pink tinge. It is also
available as an aqueous
solution
Red-brownish liquid or light
brown powder with a pink tinge
Light red-brownish liquid or
powder
Identification
pH Between 3.7 and 5.5
(4% solution)(a)
3.7–5.5 (4% solution)
Solubility Very soluble in water, insoluble in ethanol, acetone, methanol
and butanol
Foam Dissolve 0.5 g of powder
extract in 9.5 g of water or
1 mL of liquid extract in 9 ml of
water. Add 1 mL of this mixture
to 350 mL of water in a 1,000-
mL graduated cylinder. Cover
the cylinder, vigorously shake it
30 times, and allow settling.
Record the foam level (mL)
after 30 min. Typical values are
150 mL of foam
Dissolve 0.5 g of the powder
form in 9.5 mL of water or
1 mL of the liquid form in 9 ml
of water. Add 1 mL of this
solution to 350 mL of water in
a 1,000-mL graduated cylinder.
Cover the cylinder, vigorously
shake it 30 times, and allow
settling. Record the foam
volume (mL) after 30 min.
Typical volumes are about
260 mL
Chromatography The retention time of major peak of the sample corresponds to
the major saponin peak (QS-18) of the standard
Colour and
turbidity
Powder form only: Dissolve
0.5 g in 9.5 g of water. The
solution is not turbid
Determine the absorbance of
the solution against water at
520 nm. The absorbance is less
than 1.2
Powder form only: Dissolve
0.5 g in 9.5 mL of water. The
solution shall not be turbid.
Determine the absorbance of
the solution against water at
520 nm. The absorbance shall
be less than 0.7
Purity
Water Not more than 6,0% (Karl
Fischer method) (powder
form only)
Powder form: not more than 6% (Karl Fischer Method)
Loss on drying Liquid form: 50 to 80% (2 g,
105°, 5 h)
Liquid form: 50 to 90% (2 g,
105°, 5 h)
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The Panel noted that existing EU specifications do not describe any range for saponins content in
the food additive. While the JECFA specifications differentiate two types of Quillaia extracts, Type 1
and Type 2, containing different percentages of saponins. The Panel also noted that the interested
parties for the re-evaluation and the applicant for the extension of use as a food additive in flavourings
have provided analytical data for liquid forms of Quillaia extract Type 1 and Type 2 (Documentation
provided to EFSA n. 6, 8) and in addition to the parameters requested in the EU specifications,
information on the percentage of saponins and tannins were determined, as well as percentage of ash
(on a dried basis) that according to JECFA (2005) reflects the content of calcium oxalate. In addition,
data on the percentage of protein and invert sugars were provided by the interested parties
(Documentation provided to EFSA n. 6). The Panel considered that a similar differentiation of the
Quillaia extracts should be presented in the EU specifications, e.g. as E 999(i) and E 999(ii), including
the percentage range for saponins (including a description of the principle of the method of analysis to
quantify the content of saponins in line with the JECFA specifications), polyphenols (including tannins),
protein, polysaccharides including fibre, reducing sugars and a maximum limit for calcium oxalate.
The Panel noted that according to information from industry (Documentation provided to EFSA n. 6)
the formula weight of ‘monomeric saponins range from ca. 1,800 to ca. 2,800, consistent with a
triterpene with 8–10 monosaccharide residues’ while the formula weight in the JECFA specifications for
Quillaia extract Type 1 and Type 2 is described as ‘monomeric saponins range from ca. 1,800 to ca.
2,300’.
Information has been provided on the content of toxic elements in two different batches of Quillaia
extract (Type 1) and of Quillaia extract (Type 2): lead (0.26–0.08 mg/kg), mercury (< 0.01 mg/kg) and
arsenic (0.18–0.11 mg/kg) (Documentation provided to EFSA n. 6). The levels of lead, mercury, and
arsenic analysed were all far below the levels as defined in the Commission Regulation (EU) No 231/2012,
of 2, 2 and 1 mg/kg for arsenic, lead and mercury, respectively. Contamination at those levels could have
a significant impact on exposure to these toxic elements, which are already close to the health-based
guidance values or benchmark doses (lower confidence limits) established by EFSA (EFSA CONTAM Panel,
2009, 2010, 2012a,b, 2014).
The Panel noted that, according to the JECFA specifications, Quillaia extract Type 1 and Type 2 as
liquid products are usually preserved with sodium benzoate. According to Annex III Part 2 ‘food
additives other than carriers in food additives’ of the Regulation (EC) No 1333/2008, sodium benzoate
can only be used in colour preparations.
Because of the botanical origin, Quillaia extract can be subject to microbiological contamination.
Interested parties have proposed microbiological specifications (Table 2). Additionally, according to the
certificate of analysis, the presence of Escherichia coli, Salmonella and S. aureus is tested negative
(Documentation provided to EFSA n. 6). The Panel agreed with the inclusion of microbiological
parameters in the EU specifications for E 999 as proposed in Table 2, including also specifications for
the absence of E. coli, Salmonella and S. aureus.
Commission Regulation
(EU) No 231/2012
JECFA (2006c) Type 1
[INS No 999(i)]
JECFA (2014) Type 2
[INS No 999(ii)]
Ash Not more than 14% on a dried
basis (use 1.0 g for powder
samples; for liquid samples, use
the residue from loss on drying)
Not more than 5% on a dried
basis (use 1.0 g for powder
samples; for liquid samples, use
the residue from Loss on
drying)
Tannins Not more than 8% on a dried basis
Arsenic Not more than 2 mg/kg
Lead Not more than 2 mg/kg Not more than 2 mg/kg
Mercury Not more than 1 mg/kg
(a): According to recital 33) of Regulation (EC) 231/2012, the current specification relating to the pH range should be adjusted
in order to bring it in line with JECFA.
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One of the interested parties submitted a detailed report summarising soluble oxalates (oxalic acid)
levels in five samples of Quillaia extract (Type 1) and three samples of Quillaia extract (Type 2). In all
cases, the amount of oxalic acid in the liquid products was below the limit of quantification (LOQ) for
the chromatographic method employed (i.e. 5 mg/L). In four out of the five samples of Quillaia extract
(Type 1), the level was also below the limit if detection (LOD) (1 mg/L). The Panel considered that
these levels are far below the typical level of oxalic acid identified in the EFSA compendium of
botanicals (EFSA, online), i.e. 11% in the bark of the plant (110,000 mg/L).
In view of the botanical origin of Quillaia extract, limits for the presence of pesticides should be
considered. According to analytical data provided by industry (Documentation provided to EFSA n. 6), no
carbamates, organohalides and organophosphates pesticides were detected in the Quillaia extract (Types
1 and 2) batches tested. The Panel noted that MRLs for pesticides set under Regulation (EC) 396/2005
apply to Quillaja saponaria (Soapbark tree (bark)); Quillaja saponaria is listed in Part B of Annex I under
the category of Herbal infusions from any other parts of the plant (product code 0639000). Thus, MRLs
established for this commodity code equally apply to Quillaja saponaria. For processed products derived
from Quillaia extract, the provisions of Article 20 are applicable, meaning that the changes in the levels of
pesticide residues caused by processing need to be taken into account.
3.1.3. Manufacturing process
According to information provided by interested parties, the source material for the production of
Quillaia extracts (Types 1 and 2) is the bark or wood of the tree Quillaja saponaria Molina (family
Rosaceae), an evergreen tree native to China and South America (Documentation provided to EFSA n. 6).
Quillaia extract (Type 1) is obtained by the aqueous extraction of the milled inner bark or of the
wood of pruned stems and branches of the tree. This extraction process is followed by clarification,
filtration, ultrafiltration, concentration and pasteurisation (Documentation provided to EFSA n. 6).
Quillaia extract (Type 2) is obtained by either chromatographic separation or ultrafiltration of the
Type 1 extract, to remove most non-saponin solids, such as calcium oxalate, sugars, tannins and other
polyphenols (Documentation provided to EFSA n. 6).
The Panel noted that, in recent literature, ultrasound-assisted extraction methods are described to
improve the extraction yield of saponins from Quillaja saponaria Molina (Cares et al., 2010; Gaete-
Garreton et al., 2011).
According to JECFA (2005), the traditional method for isolating Quillaia extracts for commercial use
is through the milling of whole wood (including wood with bark and small branches) followed by water
extraction at 70–80°C.
– To produce Quillaia extract (Type 1), the aqueous extract is stabilised by the addition of
stabilising agents (e.g. PVP or egg albumin), followed by filtration with diatomaceous earth to
remove compounds that tend to precipitate during storage (e.g. protein–polyphenol
complexes). The commercial forms are spray-dried powders or concentrated liquids (normally
550 g/L solids) which may contain sodium benzoate (~ 0.5 g/L) or ethanol.
– To produce Quillaia extract (Type 2), Type 1 extract is further purified by chromatography or
ultrafiltration to remove most non-saponin solids, such as calcium oxalate, sugars, tannins,
and polyphenols. Quillaia extract (Type 2) may contain 65–90% saponins.
3.1.4. Methods of analysis in food
Based on information provided by interested parties, saponins in Quillaia extracts are analysed by
reverse-phase high performance liquid chromatography (RP-HPLC) using the method described by San
Martın and Briones (2000).
Table 2: Microbiological specifications for Quillaia extract (Types 1 and 2) as proposed by interested
parties (Documentation provided to EFSA n. 6)
Type 1 Type 2
Parameter Limit (CFU/g) Limit (CFU/g)
Aerobic plate count < 5,000 < 100
Yeast < 100 < 10
Mould < 100 < 10
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In the evaluation by FSANZ (2013), a method to determine the content of saponins in finished
beverages using RP-HPLC is mentioned.
In literature, other methods to analyse saponins are described (Kensil and Marciano, 1991; Kensil
et al., 1991; JECFA, 2005; Kite et al., 2007; Cheok et al., 2014).
3.1.5. Stability of the substance, and reaction and fate in food
Kartnig and Ri (1973) reported that the concentration of saponins from Quillaia bark in aqueous
solutions may decrease by up to 8% during the first 14 days and by up to 9.3% by day 60 of storage.
Levels then remain constant for at least the next four months.
In a study by Mitra and Dugan (2000), the authors studied the interaction between cholesterol and
quillaia saponin, by measuring the effect of cholesterol on the surface and micellar properties of quillaia
saponin solutions. Data show that, at well-defined critical micelle concentrations (cmc), cholesterol and
saponin mixtures form micelles. The cmc for saponin solutions saturated with cholesterol was generally
higher than that for saponin alone. The increase was dependent on the source of the saponin and on its
composition. The addition of salt decreased the cmc values; the temperature dependence of these values
was more complex. Surface adsorption studies showed that cholesterol preferentially adsorbs at the air/
water interface, forming a closely packed monolayer. Saponin partially displaced the cholesterol at high
saponin concentrations. Finally, the size, the intrinsic viscosity and the aggregation number of the
cholesterol/saponin micelles are larger compared to those of saponin micelles alone; the radius of the
micelles being between 20% and 40% larger at 25°C. According to the authors, the results indicated that
cholesterol most likely solubilises within quillaia saponin micelles, and therefore, has a substantial impact
on the micelle structure and the energetics of micelle formation.
3.2. Authorised uses and use levels
Maximum levels of Quillaia extract (E 999) have been defined in Annex II to Regulation (EC) No
1333/2008 on food additives, as amended. In this document, these levels are named maximum
permitted levels (MPLs).
Currently, Quillaia extract (E 999) is an authorised food additive in the EU at an MPL of 200 mg/L,
calculated as anhydrous extract, in flavoured drinks, and in cider and perry (excluding cidre bouche)
(Table 3).
Quillaia extract (E 999) is not authorised according to Annex III to Regulation (EC) No 1333/2008.
3.2.1. Proposed extension of use as a food additive in flavourings
In addition to the re-evaluation of this food additive, the current opinion considers the proposed
inclusion of Quillaia extract (E 999) (Type 1) in Annex III Part 4 ‘Food additives including carriers in
food flavourings’ of Regulation (EC) No 1333/2008. This extension of use is limited to the food
categories and the corresponding proposed MPLs in the final food, as reported in Table 4.




Food category name Restrictions/exception
MPL (mg/L or mg/kg as
appropriate)
14.1.4 Flavoured drinks 200(a)
14.2.3 Cider and perry Excluding cidre bouche 200(a)
MPL: maximum permitted level.
(a): Calculated as anhydrous extract.
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3.3. Exposure data
3.3.1. Reported use levels or data on analytical levels of Quillaia extract (E 999)
Most food additives in the EU are authorised at a specific MPL. However, a food additive may be
used at a lower level than the MPL. Therefore, information on actual use levels is required for
performing a more realistic exposure assessment.
In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission
Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued a
public call12 for occurrence data (usage level and/or concentration data) on Quillaia extract (E 999). In
response to this public call, updated information on the actual use levels of this additive in foods was
made available to EFSA by industry. No analytical data were made available by the Member States.
Summarised data on reported use levels in foods provided by industry
FoodDrinkEurope (FDE) provided EFSA with data on use levels (n = 4) of Quillaia extract (E 999) in
foods for the two food categories in which Quillaia extract (E 999) is authorised. The three use levels
for FC 14.1.4. Flavoured drinks were for a niche product.
Appendix B provides data on the use levels of Quillaia extract (E 999) in foods as reported by FDE.
3.3.2. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in
the market worldwide. It contains information of over 2.9 million food and beverage products of which
more than 1,100,000 are or have been available on the European food market. Mintel started covering
EU’s food markets in 1996, currently having 20 out of its 28 member countries and Norway
represented in the Mintel GNPD.13
For the purpose of this Scientific Opinion, the Mintel’s GNPD14 was used for checking the labelling
of food and beverage products and food supplements for Quillaia extract (E 999) within the EU’s food
market as the database contains the compulsory ingredient information on the label.
According to the Mintel’s GNPD, Quillaia extract (E 999) was labelled on 63 products belonging to
six food subcategories: Carbonated Soft Drinks (n = 46), Beer (n = 9), Poultry Products (n = 3),
Beverage Concentrates (n = 1), RTD (Iced) Tea (n = 1) and Coffee (n = 1). The products were
published in this database between January 2013 and August 2018. The Panel noted that Quillaia
extract (E 999) is labelled on a few products for which a new authorisation has been requested.
Appendix C lists the percentage of the food products labelled with Quillaia extract (E 999) out of the
total number of food products per food subcategory for the six food subcategories. The percentages
ranged from 0.1% or less in five food subcategories to 0.7% in Mintel’s GNPD food subcategory
Table 4: Proposed uses of Quillaia extract (E 999) as a food additive in flavourings according to





Proposed level in the final
food(a) (mg/L or mg/kg as
appropriate)
05.2 Other confectionery including breath refreshening microsweets 18
05.3 Chewing gum 9
12.5 Soups and broths 10
14.1.5 Coffee, tea, herbal and fruit infusions, chicory; tea, herbal and
fruit infusion and chicory extracts; tea, plant, fruit and cereal
preparations for infusions, as well as mixes and instant mixes of
these products
6
15.1 Potato-, cereal-, flour- or starch-based snacks 1
(a): As anhydrous extract.
12 https://www.efsa.europa.eu/en/data/call/160524
13 Missing Bulgaria, Cyprus, Estonia, Latvia, Lithuania, Luxembourg, Malta and Slovenia.
14 http://www.gnpd.com/sinatra/home/ accessed on 18/10/2018.
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‘Carbonated Soft Drinks’. The average percentage of foods labelled to contain Quillaia extract (E 999) and
belonging to food subcategories with at least one food labelled with the additive was 0.2%.
3.3.3. Food consumption data used for exposure assessment
EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive
Database) has been populated with national data on food consumption at a detailed level. Competent
authorities in the European countries provide EFSA with data on the level of food consumption by the
individual consumer from the most recent national dietary survey in their country (cf. Guidance of
EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a). Consumption surveys added in the Comprehensive database in 2015 were
also taken into account in this assessment.11
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons should be interpreted with caution. Depending on the food
category and the level of detail used for exposure calculations, uncertainties could be introduced owing
to possible subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless,
the EFSA Comprehensive Database represents the best available source of food consumption data
across Europe at present.
Food consumption data from the following population groups were used in the exposure assessment:
infants, toddlers, children, adolescents, adults and the elderly. For the present assessment, food
consumption data were available from 33 different dietary surveys carried out in 19 European countries
(Table 5).
Consumption records were codified according to the FoodEx classification system (EFSA, 2011b).
Nomenclature from the FoodEx classification system has been linked to the Food Classification System
(FCS) as presented in Annex II of Regulation (EC) No 1333/2008, part D, to perform exposure
estimates. In practice, FoodEx food codes were matched to the FCS food categories.
Food categories considered for the exposure assessment of Quillaia extract (E 999)
The food categories in which the use of Quillaia extract (E 999) is currently authorised were
selected from the nomenclature of the EFSA Comprehensive Database (FoodEx classification system),
at the most detailed level possible (up to FoodEx Level 4) (EFSA, 2011b).
Table 5: Population groups considered for the exposure estimates of Quillaia extract (E 999)
Population Age range
Countries with food consumption surveys covering more
than 1 day
Infants From more than 12 weeks up to
and including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, UK
Toddlers(a) From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy,
Netherlands, Spain, UK
Children(b) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland,
France, Germany, Greece, Italy, Latvia, Netherlands, Spain,
Sweden, UK
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Netherlands, Spain, Sweden, UK
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Romania,
Spain, Sweden, UK
The elderly(b) From 65 years of age and older Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Romania, Netherlands, Sweden, UK
(a): The term ‘toddlers’ in the EFSA Comprehensive Database corresponds to ‘young children’ in Regulations (EC) No 1333/2008
and (EU) No 609/2013.
(b): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
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For FC 14.2.3 Cider and perry, the exception ‘excluding cidre bouche’ could not be taken into
account, and therefore the whole food category was considered in the different exposure scenarios in
the exposure assessment (Appendix D).
The Panel noted that three of the four use levels referred to niche products (referring to FC 14.1.4
flavoured drinks). These levels are only considered in the refined exposure assessment if no other use
levels are available for the food categories to which the niche products belong. As this was the case,
these use levels were included in the refined assessment.
Furthermore, the Panel also considered the five food categories for which an extension of use as a
food additive in flavourings was sought at the level of the proposed MPL in two additional exposure
scenarios (Table 4).
3.4. Exposure estimates
3.4.1. Exposure to Quillaia extract (E 999) from its use as a food additive
The Panel estimated chronic exposure to Quillaia extract (E 999) for the following population
groups: infants, toddlers, children, adolescents, adults and the elderly. Dietary exposure to Quillaia
extract (E 999) was calculated by multiplying Quillaia extract (E 999) concentrations for each food
category (Appendicies D and E) with their respective consumption amount per kilogram of body weight
for each individual in the Comprehensive Database. The exposure per food category was subsequently
added to derive an individual total exposure per day. These exposure estimates were averaged over
the number of survey days, resulting in an individual average exposure per day for the survey period.
Dietary surveys with only one day per subject were excluded as they are considered as not adequate
to assess repeated exposure.
This was carried out for all individuals per survey and per population group, resulting in distributions of
individual exposure per survey and population group (Table 5). Based on these distributions, the mean
and 95th percentiles of exposure were calculated per survey and per population group. High percentile
exposure was only calculated for those population groups where the sample size was sufficiently large to
allow calculation of the 95th percentile of exposure (EFSA, 2011a). Therefore, in the present assessment,
high levels of exposure for infants from Italy and for toddlers from Belgium, Italy and Spain were not
estimated.
Exposure assessment to Quillaia extract (E 999) was carried out by the FAF Panel based on four
different sets of concentration data: (1) MPLs as set down in the EU legislation (defined as the
regulatory maximum level exposure assessment scenario), (2) reported use levels (defined as the
refined exposure assessment scenario), (3) regulatory maximum level exposure assessment together
with the proposed maximum levels in the final food for the extension of use and (4) brand-loyal
refined estimated exposure scenario together with the proposed maximum levels in the final food for
the extension of use. These scenarios are discussed in detail below.
Regulatory maximum level exposure assessment scenarios for exposure to Quillaia
extract (E 999) using the current MPL
The regulatory maximum level exposure assessment scenario of Quillaia extract (E 999) was based
on the MPLs as set in Annex II to Regulation (EC) No 1333/2008 and listed in Table 3.
The Panel considers the exposure estimates derived following this scenario as the most
conservative since it is assumed that the consumer will be continuously (over a lifetime) exposed to
Quillaia extract (E 999) present in food at MPL.
Refined exposure assessment scenario for exposure to Quillaia extract (E 999) using the
reported use levels
The refined exposure assessment scenario is based on use levels reported by food industry. This
exposure scenario can consider only food categories for which these data were available to the Panel.
Appendix D summarises the concentration levels of Quillaia extract (E 999) used in the refined
exposure assessment scenario. Based on the available data set, the Panel calculated two refined
exposure estimates based on two model populations:
• The brand-loyal consumer scenario: It was assumed that a consumer is exposed long-term to
Quillaia extract (E 999) present at the maximum reported use level for one food category. This
exposure estimate was calculated as follows:
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– Combining food consumption with the maximum reported use level for the main
contributing food category at the individual level.
– Using the mean of the typical reported use level for the other food category.
• The non-brand-loyal consumer scenario: It was assumed that a consumer is exposed long-
term to Quillaia extract (E 999) present at the mean reported use levels in food. This exposure
estimate is calculated using the mean of the reported use levels for the two food categories.
Exposure scenarios including proposed extension of use of Quillaia extract (E 999) as a
food additive in flavourings
To estimate the potential exposure to Quillaia extract (E 999) due to its proposed extension of use
as a food additive in flavourings, two exposure scenarios were calculated. First, the regulatory
maximum level exposure assessment scenario of Quillaia extract (E 999) was calculated as described
above, including also the proposed maximum levels in the final food for the extension of use submitted
by the applicant and listed in Table 4.
Second, a refined estimated exposure scenario was calculated based on maximum use levels
reported by food industry and the proposed maximum levels in the final food for the extension of use
submitted by the applicant.
Appendix E summarises the concentration levels of Quillaia extract (E 999) used in both scenarios.
Dietary exposure to Quillaia extract (E 999) from the current authorised uses
Table 6 summarises the estimated exposure to Quillaia extract (E 999) from its use as a food
additive in six population groups (Table 5) according to the different exposure scenarios. Detailed
results per population group and survey are presented in Appendix F.
In the regulatory maximum level exposure assessment scenario, mean exposure to Quillaia extract
(E 999) from its use as a food additive ranged from 0 mg/kg bw per day in infants and toddlers to
3.0 mg/kg bw per day in children. The 95th percentile of exposure to Quillaia extract (E 999) ranged
from 0 mg/kg bw per day in infants and toddlers to 9.6 mg/kg bw per day in toddlers.
In the brand-loyal refined estimated exposure scenario, mean exposure to Quillaia extract (E 999)
from its use as a food additive ranged from 0 mg/kg bw per day in infants and toddlers to 0.3 mg/kg
bw per day in toddlers and children. The high exposure to Quillaia extract (E 999) ranged from 0 mg/kg
bw per day in infants and toddlers to 1.0 mg/kg bw per day in toddlers. In the non-brand-loyal scenario,
mean exposure to Quillaia extract (E 999) from its use as a food additive ranged from 0 mg/kg bw per
day in infants and toddlers to 0.3 mg/kg bw per day in children. The 95th percentile of exposure to
Quillaia extract (E 999) ranged from 0 mg/kg bw per day in infants and toddlers to 0.8 mg/kg bw per
day in toddlers.
Table 6: Summary of estimated exposure to Quillaia extract (E 999) from its use as a food additive
in the regulatory maximum level exposure assessment scenario and in the refined
exposure scenarios, in six population groups (minimum–maximum across the dietary

















Regulatory maximum level exposure assessment scenario
 Mean 0–0.5 0–2.7 0.2–3.0 0.3–2.3 0.1–1.0 < 0.1–0.3
 95th percentile 0–3.2 0–9.6 1.0–7.6 1.2–5.3 0.5–3.4 0.2–1.2
Refined estimated exposure assessment scenario
Brand-loyal scenario
 Mean 0–0.1 0–0.3 < 0.1–0.3 < 0.1–0.2 < 0.1–0.1 < 0.1–< 0.1
 95th percentile 0–0.3 0–1.0 0.1–0.8 0.1–0.5 0.1–0.4 < 0.1–0.2
Non-brand-loyal scenario
 Mean 0–< 0.1 0–0.2 < 0.1–0.3 < 0.1–0.2 < 0.1–0.1 < 0.1–< 0.1
 95th percentile 0–0.3 0–0.8 0.1–0.6 0.1–0.5 < 0.1–0.3 < 0.1–0.1
bw: body weight.
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The main contributing food category to the total mean exposure estimates for all population groups
was flavoured drinks in all exposure scenarios (Appendix G).
Dietary exposure to Quillaia extract (E 999) including its proposed extension of use as a
food additive in flavourings
Table 7 summarises the anticipated exposure to Quillaia extract (E 999) from its use as a food
additive in six population groups (Table 5), including its proposed extension of use. Detailed results per
population group and survey are presented in Appendix H. In these scenarios, the maximum levels
proposed for the extension of use (Table 4) were taken into account together with the current MPLs
(Table 3) or maximum use levels reported by industry (Appendix E).
In both scenarios, exposure estimates were almost identical to those considering only the current
food categories in which Quillaia extracts (E 999) is authorised. Also the main food category (FC 14.1.4
Flavoured drinks) contributing to the exposure remained the same for most age groups, except for
infants and the elderly in the refined exposure assessment scenario. In this exposure scenario, FC 12.5
Soups and broths contributed most to the exposure in infants and FC 14.1.5 Coffee, tea, herbal and
fruit infusions, chicory; tea, herbal and fruit infusions and chicory extracts; tea, plant, fruit and cereal
preparations for infusions, as well as mixes and instant mixes of these products contributed most to
the exposure in the elderly (Appendix I).
Uncertainty analysis
Uncertainties in the exposure assessment of Quillaia extract (E 999) have been discussed above. In
accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure
assessment (EFSA, 2007), the following sources of uncertainties have been considered and
summarised in Table 8.
Table 7: Summary of anticipated exposure to Quillaia extract (E 999) from its use as a food
additive and including its proposed extension of use as a food additive in flavourings, in
the regulatory maximum level exposure assessment scenario and in the refined exposure
scenario, in six population groups (minimum–maximum across the dietary surveys in mg


















Regulatory maximum level exposure assessment scenario + proposed extension of use
 Mean < 0.1–0.5 < 0.1–2.8 0.2–3.1 0.3–2.3 0.1–1.0 < 0.1–0.4
 High level (95th
percentile)
0–3.2 < 0.1–9.6 1.1–7.6 1.2–5.4 0.5–3.4 0.2–1.2
Refined exposure assessment scenario + proposed extension of use
 Mean < 0.1–0.1 < 0.1–0.3 < 0.1–0.3 < 0.1–0.3 < 0.1–0.2 < 0.1–0.1
 High level (95th
percentile)
0–0.3 < 0.1–1.0 0.1–0.8 0.1–0.6 0.1–0.4 < 0.1–0.3
bw: body weight.
Table 8: Qualitative evaluation of influence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data: different methodologies/representativeness/underreporting/misreporting/no
portion size standard
+/–
Methodology used to estimate high percentiles (95th) long-term (chronic) exposure based on
data from food consumption surveys covering only a few days
+
Correspondence of reported use levels to the food items in the EFSA Comprehensive Food
Consumption Database: uncertainties to which Types of food the levels refer to
+/–
Uncertainty in possible national differences in use levels of food categories +/–
Concentration data: use levels considered applicable to all foods within the entire food category,
whereas on average 0.2% of the foods, belonging to a food category with foods labelled with
additive, was labelled with the additive
+
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Quillaia extract (E 999) is currently authorised in two food categories. As use levels were reported
by industries for both categories, all current authorisations were taken into account in the assessment
(without taking into account the restriction for one of the two food categories (Section 3.3.3)).
The Panel noted that information from the Mintel GNPD (Appendix C) indicated that no cider or
perry were labelled with Quillaia extract (E 999). Apart from flavoured drinks, in which the food
additive is authorised, only a few other products that are not authorised to contain Quillaia extract
(E 999) were labelled with the food additive (beer, poultry products, coffee and tea).
Overall, the Panel considered that the uncertainties summarised in Table 8 resulted in an
overestimation of the exposure to Quillaia extract (E 999) from its use as a food additive according to
Annex II in both the MPL and refined exposure scenario. This was also true for the two exposure
scenarios considering the requested extension of use of Quillaia extract (E 999) as a food additive in
flavourings in five food categories according to Annex III.
3.4.2. Exposure to Quillaia extract from other sources
The Panel noted that Quillaia extract is used in few preparations as a drug available in some EU
Member States for use as an expectorant (Martindale, online) and this may be an additional source of
exposure.
3.4.3. Exposure to sodium benzoate from Quillaia extract (E 999)
According to the applicant, as also mentioned in the JECFA specifications (JECFA, 2006c, 2014),
sodium benzoate is used in liquid preparations of Quillaia extracts (E 999).
Currently, according to Annex III Part 2 ‘food additives other than carriers in food additives’ of the
Regulation (EC) No 1333/2008, sodium benzoate can only be used in colour preparations. The applicant
proposed the addition of sodium benzoate (E 211) to Annex III of Regulation (EC) No 1333/2008 as a
preservative for use in liquid formulations of Quillaia extracts (E 999) in line with the JECFA
specifications (Documentation provided to EFSA n. 6).
The maximum level of sodium benzoate used in Quillaia extracts preparation was reported to be
1,000 mg/kg of the final preparation according to the applicant (Documentation provided to EFSA n. 6).
Based on the above information, the Panel estimated a high level of exposure to sodium benzoate
for the regulatory maximum level exposure assessment scenario (for the current MPLs) and the refined
exposure assessment scenario (using maximum reported use levels for the current uses and proposed
maximum levels in the final food for the extension of uses). High level estimates (95th percentile) of
sodium benzoate from the use of a preparation of Quillaia extracts (E 999) – containing sodium
benzoate – were maximally 9.6 and 1.0 lg/kg bw per day, respectively for the two scenarios.
Exposure to benzoic acid–benzoates (E 210–213) from their authorised use according to Annex II
(Regulation No 1333/2008) and via food categories which may contain benzoic acid–benzoates due to
carry-over (for which data were available), was estimated to range between 0.8 mg/kg bw per day at
the mean for adolescents and the elderly and 6.9 mg/kg bw per day at the 95th percentile for toddlers
(EFSA ANS Panel, 2016). Based on these estimates and comparing the highest exposure estimate for
benzoates (EFSA ANS Panel, 2016) to the lowest coming from Quillaia extract (current opinion) and
Sources of uncertainties Direction(a)
Food categories selected for the exposure assessment: inclusion of food categories without
considering the restriction/exception (1 FC for all scenarios)
+
Regulatory maximum level exposure assessment scenario (including also the extension of use):
• exposure calculations based on the MPL according to Annex II to Regulation (EC)
No 1333/2008 (and on the proposed maximum levels in the final food for its extension
of use)
+
Refined exposure assessment scenarios (including also the extension of use):
• exposure calculations based on the proposed maximum levels in the final food for
extension of use
• exposure calculations based on the maximum levels reported use from industries
+
+/–
FC: food category; MPL: maximum permitted level.
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
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the lowest exposure estimate for benzoates (EFSA ANS Panel, 2016) to the highest coming from
Quillaia extract (current opinion), the Panel calculated that the additional exposure to sodium benzoate
(E 212) coming from the use of Quillaia extracts (E 999) would be in the range 0.01% to 0.13%.
3.5. Biological and toxicological data
The Panel assumed that the test materials used in toxicological studies described as Quillaia extract
approximated to Quillaia extract Type 1 as described in JECFA specifications (2006c).
3.5.1. Absorption, distribution, metabolism and excretion
Fieger (1918) reported that quillaia saponins were not or only to a limited degree detected in urine
from dogs (two animals) after administration.
B€ack (1918) reported that quillaia saponins were excreted in the faeces after oral administration to
hens and dogs. Their presence was detected through their haemolytic action on erythrocytes isolated
from a variety of species.
Ewart (1931) reported that saponins (not further specified) may be hydrolysed into sugars and
sapogenins by diastase, animal trypsin and pancreatic juice. The author also reported that the
saponins were resistant to dialysis, but that their absorption through the alimentary canal may be
favoured by irritation or inflammation.
Hostettmann and Marston (1995) stated that triterpene saponins in general are poorly absorbed
and either excreted unchanged or metabolised in the gut in animals (species not specified) after oral
administration. Information on the fate of saponins in the gut (species not specified) is generally
lacking but any breakdown of saponins is most likely caused by gut microorganisms, intestinal
enzymes or gastric juice.
The Panel considered that the extent and the quality of the available data on the absorption,
distribution, metabolism, excretion (ADME) of Quillaia extract saponins were very limited and that no
conclusions could be drawn based on studies with Quillaia extracts.
Due to the limited data and quality of studies regarding the ADME of Quillaia saponins, the
Panel therefore considered the available data on gastrointestinal (GI) metabolism and ADME for
structurally similar saponins (Appendix J). These data are described in Appendices K and L,
respectively. Based on read-across from these data, the Panel assumed that Quillaia extract saponins
share a similar fate. Thus, the Panel considered it likely that intact Quillaia extract saponins are
absorbed to a low extent; are hydrolysed in the GI tract and that the aglycon (sapogenin) is absorbed
only to a limited extent.
3.5.2. Acute toxicity
JECFA (2006a) reported a study examining the acute oral toxicity of Quillaia extracts in rats.
Sprague–Dawley rats (5 animals/sex per group) were given single oral doses of either Quillaia extract
Type 1 (8.8% saponin content of the standardised test material corresponding to 20% saponin content
on dry matter basis) or Type 2 (14% saponin content of the standardised test material corresponding
to 72% saponin content on dry matter basis) ranging from 3,000 to 20,000 mg/kg bw and were
observed for clinical signs of toxicity for the following 14 days. On the basis of the saponin content,
JECFA reported LD50 values for the two extracts of approximately 900 mg saponin/kg bw.
In a subacute study over 21 days, C57BL/6 mice (10 animals/group, sex not specified) were
administered Quillaia extract (from Garuda International, Inc and described as non-refined Quillaia
extract containing 100% water-soluble Quillaia solids) in water by oral gavage at doses of 1, 5 and
10 mg per animal (Kirk et al., 2004). One group was given 10 mg Quillaia extract on days 0 and 7, while
two other groups received 1 or 5 mg Quillaia extract per animal on days 0, 7 and 14. Mice in the 10 mg
group had a hunched back, scuffed fur and lethargy and 40% died or were euthanised within the first
week. One further animal died at day 12. Following the second dose on day 7, 40% of the mice died or
were euthanised in the 5 mg group. One further animal died after the third dose in the 5 mg group. All
mice in the 1 mg group survived the three-week trial without any gross signs of toxicity.
The Panel noted that from the limited data available, the acute toxicity for Quillaia extract was low.
3.5.3. Short-term and subchronic toxicity
Quillaia extract (source not further specified) was administered to young FDRL albino rats (5 animals/
sex/group) in the diet at 0.05% Quillaia extract (equivalent to 45 mg/kg bw per day) for 12 weeks (Oser,
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1966). Blood erythrocyte counts, erythrocyte fragility tests and haemoglobin determinations were
performed at weeks 4, 8 and 12. Total and differential leucocyte counts, blood glucose and non-protein
nitrogen were determined at week 12. At termination, the weights of the liver, kidneys, spleen, heart and
adrenals were determined. Histological examinations were made of the liver, kidneys, adrenals, gonads,
lymph nodes and bone marrow. Fifteen additional organs or tissues were examined microscopically in
three rats of each sex. Growth response, behaviour and appearance of the animals were monitored. The
authors reported that no adverse effects associated with the addition of Quillaia extract to the diet were
observed.
Gaunt et al. (1974) treated weanling CFE strain rats (15 animals/sex per group) in the diet for 13
weeks with 0%, 0.6%, 2% or 4% Quillaia extract (spray-dried aqueous extract of Quillaia bark, where 15
parts of dried extract was equivalent to 100 parts of bark by weight) (description of the test material see
Appendix M). In addition, groups of 5 male and 5 female rats were fed on diets containing 0%, 2% or
4% Quillaia extract for 2 or 6 weeks. The mean daily intakes of Quillaia extract were reported as 360,
1,180 and 2,470 mg/kg bw for males, and 440, 1,370 and 3,030 mg/kg bw for females for the dietary
dose levels of 0.6%, 2% and 4%, respectively. A large series of organs were prepared for microscopic
examination. No abnormalities of behaviour or condition were seen and there was no evidence for
diarrhoea or other signs of GI irritation during the study. Food consumption was reduced in both sexes at
all dose levels and the mean intakes over the whole experimental period were statistically significantly
less than controls in mid- and high-dose females (p < 0.01). The body weights of the high-dose group
were only significantly lower than those of the control up to day 78 in males and for the first 2 weeks in
females. There were no differences in any haematological or urinary parameters between the Quillaia
extract groups and the control groups. At autopsy, statistically significant organ weight changes included
decreased relative liver weight (males at 2 and 4%, p < 0.001); decreased relative kidney weight (males
at 2% and females at 4%, p < 0.05); increased relative stomach weight (males at 2.0% and 4.0% and
females at 4%, p < 0.01); increased relative caecum weight (females at 4%, p < 0.05), increased
relative brain weight (males at 4%, p < 0.05), and increased relative thyroid weight (males at 0.6% and
females at 2%, p < 0.05). No histopathological changes attributable to Quillaia extract treatment were
reported. The authors concluded that ‘the no-untoward-effect level for Quillaia extract in this study was
0.6% Quillaia extract in the diet, equivalent to an intake of approximately 400 mg/kg bw per day’.
Jcl:Wistar rats (12 animals/sex per group) were given 1,200 mg/kg bw per day Quillaia extract (a
12% solution, equivalent to 100 mg sapogenin/kg bw per day) as positive control in deionised water
by oral gavage for 90 days (Kawaguchi et al., 1994). The Panel noted that administration by gavage
for 90 days of a bolus dose of the extract resulted in local toxicity as evidenced by inflammatory
changes of the larynx, trachea and the forestomach, debility and death or killing for humane reason of
6 males and 2 females.
The Panel noted a no observed adverse effect level (NOAEL) of 0.6% Quillaia extract
(approximately 400 mg/kg bw per day) from a 13-week study in rats in which relative organ weights
were changed at the next higher dose of 1,200 mg/kg bw per day (Gaunt et al., 1974). The Panel also
noted that no histopathological changes were observed at any dose.
3.5.4. Genotoxicity
Further to a request for additional information, the applicant and the interested parties for the food
additive Quillaia extract (E 999) submitted results from new genotoxicity studies, conducted in
accordance with the requirements of the EFSA Guidance on genotoxicity testing (EFSA Scientific
Committee, 2011). According to the applicant, a Quillaia Extract Type 1 was selected based on the
assumption that the material chosen would represent a worst case exposure scenario to both saponins
and impurities (for more information on characterisation of the test material see Appendix N).
In vitro
A bacterial reverse mutation assay was conducted with a lot of Quillaia extract Type 1 (Appendix N)
in accordance with OECD TG 471 and in compliance with good laboratory practice (GLP)
(Documentation provided to EFSA n. 8.).
The Quillaia extract was tested in vitro for its ability to induce mutations in four strains of
Salmonella Typhimurium (TA1535, TA1537, TA98 and TA100) and in one of E. coli (strain WP2 uvrA). A
range-finder experiment was performed to determine the bacteriotoxic range of the test item under
plate incorporation conditions in TA98 and WP2 uvrA, in the presence and absence of S9 mix (derived
from livers of Aroclor 1254 treated rats). Mutation tests were then performed, using the plate
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incorporation method and pre-incubation method, both in presence and absence of S9 mix. Bacteria
were exposed to the test item dissolved in sterile water; the latter was also the negative control.
Concentrations of Quillaia extract were corrected for saponin content and dosed up to 5 lL saponins/
plate in a first experiment under plate incorporation conditions and in a second experiment under pre-
incubation conditions, in all strains in the presence and absence of the S9 mix. All negative and
positive controls fulfilled the acceptance criteria, demonstrating the sensitivity of the assay and
metabolic activity of the S9 preparations. No precipitations or signs of toxicity were observed in any
experiment. There were no dose-related or statistically significant increases in revertant numbers
observed in any strain at any concentration of Quillaia extract compared with vehicle controls, in the
presence or absence of S9 mix, under plate incorporation or pre-incubation conditions. Values at all
concentrations of Quillaia extract (with all strains) were also within historical negative control ranges.
Thus, Quillaia extract showed no mutagenic potential in the bacterial reverse mutation assay at
concentrations up to 21.55 lL Quillaia extract/plate (5 lL saponins/plate) in the absence or presence
of metabolic activation.
The same test material was used also in an in vitro mammalian cell micronucleus assay conducted in
accordance with OECD TG 487 and in compliance with GLP (Documentation provided to EFSA n. 8). This
test was carried out on TK6 human lymphoblast derived cells. A range-finder experiment was performed
to determine the cytotoxic range of the test item for each treatment condition. In the main experiment,
TK6 cells were treated with preparations of Quillaia extract, negative control (sterile water) or positive
controls in both presence and absence of metabolic activation system (S9 mix, derived from livers of
Aroclor 1254-treated rats). The treatment period was 3 h in the presence and absence of S9 mix.
Harvesting was 44 h after initiation of treatment; continuous treatment (27 h) was not performed due to
the positive result seen after the 3 h treatment in the presence of S9 mix. Treated cultures in the
absence of S9 mix were selected for analysis based on the cytotoxicity limit (concentration that resulted
in approximately 55%  5% cytotoxicity indicated by a reduction in relative increase in cell count (RICC)
to 45%  5% compared with the negative controls). In the presence of S9 mix, cultures were selected
for analysis based on the highest concentration which had an acceptable RICC. Concentrations of
Quillaia extract were corrected for saponin content and those selected for analysis were 0.002, 0.01 and
0.012 lL saponins/mL in the presence of S9 mix and 0.002, 0.01, 0.012 and 0.014 lL saponins/mL in
the absence of S9 mix. All negative and positive controls fulfilled the acceptance criteria, demonstrating
the sensitivity of the assay and metabolic activity of the S9 preparations. The highest concentration
analysed in the presence of S9 mix (0.012 lL saponins/mL) had a RICC of 72%. In the absence of
S9 mix, the highest concentration analysed (0.014 lL saponins/mL) had a RICC of 36%. In the presence
of S9 mix, there was a statistically significant increase in % micronucleated cells at 0.012 lL saponins/
mL, compared to the negative control and the mean value was outside the historical control range.
There was also a linear trend which was significant at 0.1%, indicating a dose response. There were no
other statistically significant increases in micronucleated cells at any other concentration of Quillaia
extract in the presence of S9 mix. There were statistically significant increases in % micronucleated cells
at all concentrations in the absence of S9 mix. There was also a linear trend which was significant at
0.1%, indicating a dose response. However, as the mean values at all concentrations were within the
historical negative control ranges, the results were considered to be equivocal. The authors of the study
report concluded that the Quillaia extract tested in this study was either clastogenic or aneugenic when
metabolically activated in the presence of S9 mix, while they considered the results equivocal in the
absence of S9 mix. The Panel agreed with the conclusions from the authors.
In vivo
In accordance with the applicable SC Genotoxicity guidance (EFSA Scientific Committee, 2011) the
positive and equivocal findings observed in the in vitro mammalian cell micronucleus assay were
followed up with an in vivo mammalian erythrocyte micronucleus test performed in accordance with
the OECD TG 474 and in compliance with GLP (Documentation provided to EFSA n. 8). The test was
performed on rats (strain Crl:WI(Han)).
A range-finding experiment was performed to establish the highest dose of Quillaia extract that did
not produce mortality or severe signs of clinical toxicity up to the maximum tolerated dose level (MTD).
Groups of three males and three females were dosed by oral gavage at 500, 1,250 or 2,000 mg
saponins/kg bw per day saponins (2,155, 5,387.5 or 8,620 mg Quillaia extract/kg bw per day) twice
(approximately 24 h apart) at a dose volume of 10 mL/kg. The MTD was at least 2,000 mg saponins/kg
bw per day in males and 1,250 mg saponins/kg bw per day in females. As there was no substantial
(≥ 3-fold) difference in the MTD between males and females and only limited toxicity was observed in
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the males, the main study was conducted in males only as a limit test. Blood samples were collected at
1, 2 and 4 h after the second dose for proof of target tissue (bone marrow) exposure.
For the main experiment, groups of six males were dosed by oral gavage with water (negative
controls) or Quillaia extract at the maximum dose of 2,000 mg saponins/kg bw per day (8,620 mg
Quillaia extract/kg bw per day) on two consecutive days, approximately 24 h apart. A positive control
group, also of six males, was given a single oral gavage dose of cyclophosphamide (15 mg/kg bw per
day). Two satellite groups with three males per group were dosed for checking target tissue exposure.
Blood samples for micronucleus evaluation were taken approximately 48 h after the final dose. A
minimum of 4,000 and a maximum of approximately 20,000 reticulocytes were scored by flow
cytometry for the presence of micronuclei for each animal and the frequency of micronucleated
reticulocytes was statistically analysed. Blood samples were also collected from animals of the satellite
groups 4 h after the second dose, to demonstrate bone marrow exposure in peripheral blood.
To check target tissue exposure, plasma samples from animals from the dose-range finding study
and from a satellite group of the main study were analysed for quillaic acid. This compound was
chosen as a representative of all the saponins constituting Quillaia extract, due to its high
concentration with respect to the other constituents in the test items. However, with the exception of
one case, the concentration of quillaic acid in the dose-range finding study was below the limit of
quantification. Therefore, only qualitative analysis was performed in the main study. According to the
authors of the study report, after testing samples of plasma spiked with 1% of Quillaia extract and
samples of blank plasma with and without internal standard, it was possible to confirm the presence of
quillaic acid by detecting a peak eluting at 1.35 min in the test items.
The negative and positive control groups fulfilled the acceptance criteria, demonstrating the
sensitivity of the assay. The mean frequency of micronucleated reticulocytes for animals treated with
Quillaia extract was similar to that of the negative control group. The percentage of reticulocytes (%
RET) for Quillaia extract treated animals was statistically significantly reduced (1.53 vs 3.87% in
negative control animals, i.e. 60% reduction). While the Panel considered the plasma analysis data
insufficient to demonstrate target tissue exposure, it considered that the reduction in the % RET
confirmed test item exposure and toxicity to the target tissue (bone marrow).
Thus, there was no evidence of clastogenicity or aneugenicity following oral gavage administration
of Quillaia extract up to the maximum dose level of 2,000 mg saponins/kg bw per day (8,620 mg
Quillaia extract/kg bw per day) in male rats.
The Panel noted that the in vivo micronucleus assay was performed with a lot of Quillaia extract for
which the shelf life of 18 months was already exceeded. While this may limit the reliability of the study
to a certain extent, there is no indication that would justify assuming that the use of this lot resulted in
a false-negative outcome of the study.
Accordingly, the Panel considered that the negative result of the in vivo micronucleus assay rules
out the concern for structural and numerical chromosomal aberrations that resulted from the positive
in vitro micronucleus test.
The Panel noted that this food additive is a mixture that is chemically only poorly characterised but
that from the description of its chemical composition and the analytical data provided, there is no
indication for the presence of genotoxic components in this mixture. Therefore, overall, the
Panel concluded that the data available do not indicate a concern for genotoxicity.
3.5.5. Chronic toxicity and carcinogenicity
Mouse
In an 84-week study, TO mice (48 animals/sex per group) were fed a diet containing 0, 0.1, 0.5 or
1.5% Quillaia extract (description of the test material see Appendix J), equivalent to 0, 150, 750 and
2,250 mg/kg bw per day, respectively (Phillips et al., 1979). The condition and behaviour of the
animals were frequently monitored and 16 males were weighed at weeks 0, 1, 4, 10, 14, 28, 40, 57
and 84. Blood samples were taken from 10 male and 10 female mice from the control group and the
groups receiving 0.5% and 1.5% Quillaia extract at weeks 26, 54 and 84 for the determination of
reticulocyte, erythrocyte and leucocyte counts, packed cell volume and haemoglobin concentration. At
autopsy, any macroscopic abnormalities were recorded and the brain, heart, liver, kidneys, spleen,
stomach, small intestine, caecum and testes were weighed. The weighed organs in addition to the
salivary gland, thyroid, adrenal glands, lymph nodes, aorta, pancreas, pituitary, prostate, seminal
vesicles, ovaries, uterus, urinary bladder, lungs, colon, rectum, spinal cord, skeletal muscle, eye,
Harderian gland and other tissues that appeared abnormal were prepared for microscopic examination.
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Histopathological examinations were performed on 45, 42, 41 and 43 males and on 44, 43, 43 and 46
females from the control, 0.1%, 0.5% and 1.5% groups, respectively. Survival rates and body weights
were similar in treated and control animals and there were no adverse effects on condition or
behaviour of the animals. There was a slightly lower body weight gain in high-dose males compared to
controls (reported to be statistically significant only by the end of the study although a p-value was not
given). The only statistically significant haematological change observed was in red blood cell
parameters in that there was a decrease in erythrocyte counts at week 26 in high-dose females
(p < 0.01) and in mid- and high-dose males (p < 0.05 and p < 0.01, respectively), and at week 84 in
mid-dose males (p < 0.01). There was also an increased packed cell volume at week 84 in high-dose
males (p < 0.05) and a decreased volume at week 84 in mid-dose females (p < 0.05). The relative
brain and stomach weights were statistically significantly increased in high-dose males (p < 0.05);
isolated significant changes in the weights of kidneys in males and in the small intestine in females
were observed in the 1.5% Quillaia extract dose group. The incidences of both non-neoplastic and of
neoplastic histopathological findings were similar in treated and control animals. The authors reported
a ‘no-untoward-effect level’ for Quillaia extract of 0.5% (equivalent to an intake of approximately
750 mg/kg bw per day) based on the slightly lower body weight gain and some organ weight changes
in the high-dose group (1.5%). The Panel noted that the effects reported were transient and non-dose
dependent and agreed with the conclusion of the authors.
Rats
In a 2-year study (Drake et al., 1982), weanling Wistar-derived rats (48 animals/sex per group)
were fed a diet containing 0%, 0.3%, 1.0% or 3.0% Quillaia extract (description of the test material
see Appendix M). The mean intake of Quillaia extract was reported by the authors to be 120, 390 and
1,174 mg/kg bw per day in the 0.3%, 1.0% and 3.0% group, respectively, in males; and to be 47, 497
and 1,500 mg/kg bw per day in the 0.3%, 1.0% and 3.0% group, respectively, in females. Body
weight and food and water consumption were measured approximately every second month.
According to the authors, preference tests were run before the start of the 2-year study which showed
that rats avoided the diet containing Quillaia extract. Urine was collected from 10 animals from the
control group and 10 animals from the group given 3% Quillaia extract at weeks 13, 24 and 78.
Haematological parameters (haemoglobin concentration, packed cell volume, erythrocyte and
leucocyte counts) were determined after weeks 15, 25 and 52 in 10 male and 10 female rats from
each group and after 108 weeks from all remaining animals. Serum was analysed for contents of urea,
glucose, total protein and albumin, and glutamic oxaloacetic transaminase (GOT), glutamic pyruvic
transaminase (GPT) and lactate dehydrogenase (LDH) activities. Autopsy was conducted on rats found
in a moribund condition during the study or surviving to the end of the study. The brain, heart, liver,
spleen, kidneys, stomach, small intestine, caecum, adrenal glands, gonads, pituitary and thyroid were
weighed. The weighed organs in addition to the salivary glands, thymus, various lymph nodes,
pancreas, aorta, nasal bones, lungs, trachea, oesophagus, colon, rectum, skeletal muscle, spinal cord,
sciatic nerve, uterus, prostate, seminal vesicles, urinary bladder, mammary tissue, eye, Harderian gland
and other tissues if they appeared abnormal, were examined for histopathological changes. Survival of
male rats in the 1% group was lower than controls from week 73 (only statistically significant between
weeks 85 and 91, p < 0.01 and p < 0.05, respectively). There was a trend towards lower survival
among male rats in the 3% group (only statistically significant at weeks 97 and 99, p < 0.05 at week
99, no p-value reported for week 97). Lower body weights were observed in high-dose males
(statistically significant between months 10 and 22 compared to control, with p values < 0.05 or
< 0.01); however, the mean body weights in the high-dose group compared to the control differed
between the range of 5 and 8%. Higher body weights were observed in low-dose females (statistically
significant from weeks 4 to 25 compared to control, p < 0.05). In high-dose male rats, food
consumption was consistently lower than that of the controls (not statistically significant) and water
consumption was lower than in the controls from week 71 (not statistically significant). At week 78,
the urine produced by high-dose male rats was of a higher specific gravity than that of the controls
(statistically significant p < 0.01). The only statistically significant changes (p < 0.05) in red blood cell
parameters were increased haemoglobin level at week 15 in mid-dose males and increased erythrocyte
count in mid-dose females at week 108. Total leucocyte counts were statistically significantly higher in
male rats given 1% or 3% Quillaia extract at week 15 (p < 0.05 and p < 0.01, respectively) and in
males given 3% Quillaia extract at week 25 (p < 0.01), but were statistically significantly lower at
week 108 in both sexes at 3% (p < 0.05). There were generally no significant alterations in the
differential leucocyte counts (neutrophils, eosinophils, lymphocytes and monocytes). The relative liver
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weight was decreased in males (statistically significant (p < 0.05) only at 1%) while it was increased in
high-dose females (statistically significant, p < 0.05). The relative stomach and small intestine weights
were increased in high-dose females (statistically significant, p < 0.05 and p < 0.01, respectively), the
relative weights of both full and empty caecum were increased in low- (p < 0.05 and 0.001
respectively, at 0.3%) and high-dose females ((p < 0.01 and p < 0.001, respectively, at 3%). In
general, the incidences of non-neoplastic histopathological findings were similar in treated and control
animals, except for an increased incidence of fibrosis of the heart (4/45 animals, p < 0.05) and of
glandular dilatation of the glands of the gastric mucosa (9/42 animals, p < 0.05) in low-dose females.
The only significant neoplastic finding was an increased incidence of thyroid adenoma in mid-dose
females (5/45 animals, p < 0.05). The incidence was also increased in high-dose females although not
statistically significantly (4/42 animals). The authors reported a ‘no-untoward-effect level’ for Quillaia
extract of 3% (equivalent to an intake of approximately 1,500 mg/kg bw per day, the highest dose
tested. The Panel agreed with the conclusions from the authors.
The Panel identified a NOAEL of 750 mg/kg bw per day Quillaia extract from a 84-week study in
mice and a NOAEL of 1,500 mg/kg bw per day Quillaia extract, the highest dose tested, from the
2-year study in rats. The Panel noted that there was no indication for carcinogenicity.
3.5.6. Reproductive and developmental toxicity
No reproductive or developmental toxicity data were available to the Panel.
3.5.7. Effects on the GI tract
The Panel considered the gut epithelium – as a site of contact – a potential target for any effects of
Quillaia extract. The Panel therefore focussed attention on any GI effects in the biological and
toxicological studies discussed in previous sections.
In the subchronic toxicity feeding study in weanling CFE strain specific pathogen-free (SPF) rats
(Gaunt et al., 1974), significant increases in relative stomach weights (in males in 2% and 4%, and
females in 4% diet groups; p < 0 .01) and caecum weights (in females in 4% diet group; p < 0.05)
were reported. The authors suggested that the increase in relative stomach weights may have been
due to a local irritant effect, as quillaia saponins have previously been reported to cause irritation to
the GI tract of hens and dogs (B€ack, 1918). Gross and microscopic examinations of these organs as
well as the oesophagus, colon, and rectum were conducted on rats in the control and high-dose
groups. No gross or histological abnormalities were observed upon necropsy, and the authors
remarked that there were no occurrences of diarrhoea or evidence of any other signs of GI irritation.
In the 90-day oral gavage study of Kawaguchi et al. (1994), soft faeces and diarrhoea were
reported in rats that died or were killed prior to the end of the study. The authors also reported that
similar effects were also observed in the surviving animals that received Quillaia extract. The stomach
and caecum (empty) were weighed at the end of the study. Samples of theses organs as well samples
from the oesophagus, duodenum, jejunum, ileum, colon and rectum were prepared for histological
examination. Significant increases in relative weights were reported for the caecum (males) and
significant increases in both the absolute weight and weight relative to body weight were reported for
the stomach in both sexes and the caecum in females. Histopathological examinations revealed
inflammatory changes in the forestomach (not more than 2/6 males and 3/10 females for each
observation), as well as the larynx (incidence not reported), trachea (incidence not reported) and lung
(not more than 2/6 males and 0/10 females), and atrophy of the thymus (1/6 males). The
Panel considered that many of these GI effects were associated with contact effects through its use at
a high (emulsifying) concentration (12% of saponins) which is much higher than the concentration
that E 999 is currently authorised as a food additive and therefore it was not relevant for hazard
characterisation.
In the 84-week feeding study of Phillips et al. (1979), a significant increase in relative stomach
weight was observed in high-dose males (p < 0.05; compared to male controls), and a significant
increase in absolute small intestine weight was observed in high-dose females (p < 0.05; compared to
sex-specific controls). Among other histopathological findings, chronic inflammation and degenerative
changes were reported in the GI tract of 2 (of 42), 1 (of 41) and 3 (of 43) male mice in the low-,
mid-, and high-dose groups for Quillaia extract, respectively, and in 1 (of 44) female in the control
group; however, there were no significant differences in the incidences of the lesions between the
treated and control groups with respect to histopathological abnormalities.
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In the 2-year feeding study of Drake et al. (1982), the stomach, small intestine and cecum (empty
and full) were weighed at sacrifice. Significant differences in absolute organ weights (compared to sex-
specific controls) included increased stomach, small intestine and full caecum weight (in females
provided diet containing 0.3% Quillaia extract; p < 0.05); increased empty caecum weight (in females
provided diet containing 0.3% Quillaia extract; p < 0.0001); increased small intestine and full caecum
weight (in females provided diet containing 3% Quillaia extract; p < 0.01); and increased empty
caecum weight (in females provided diet containing 3% Quillaia extract; p < 0.0001). Significant
differences in relative (to body weight) organ weights (compared to sex-specific controls) included
increased full caecum weights (in females given diet containing 0.3% Quillaia extract; p < 0.05);
increased empty caecum weight (in females given diet containing 0.3% Quillaia extract; p < 0.0001);
increased stomach weight (in females given diet containing 3% Quillaia extract; p < 0.05); increased
small intestine and full caecum weight (in females given diet containing 3% Quillaia extract; p < 0.01);
and increased empty caecum weight (in females given diet containing 3% Quillaia extract;
p < 0.0001). The authors did not attribute the changes in stomach, small intestine, and caecum
(empty and full) weights to treatment as the changes were inconsistent, occurring only in the low- and
high-dose groups, with no differences in the mid-dose group, and did not occur in the males.
Histological examinations of samples of the stomach, small intestine, cecum, oesophagus, colon, and
rectum were also conducted. The only significant difference in histopathological findings in the GI tract
was a significant increase in dilation of gastric mucosal glands (p < 0.05) in females given diet
containing 0.3% Quillaia extract; however, this effect was not attributed to treatment by the authors
as there was no evidence of a dose–response relationship despite a 10-fold increase in dietary
concentration at the high-dose level, and similar findings were not observed in the males. The authors
noted that there was ‘no evidence of irritation of the alimentary tract’ following microscopic
examination.
The Panel therefore considered that although exposure to Quillaia extract resulted in changes in GI
organ weights in several studies relevant to its use as a food additive, these changes were not
accompanied by any consistent treatment- and/or dose-related histopathological changes.
3.5.8. Hypersensitivity, allergenicity and food intolerance
Specific pathogen-free 4-week-old male ICR mice (9 animals/group) were given single doses of 0,
0.05, 0.5, 5 or 50 mg Quillaia extract (containing 45% of saponins)/kg bw by oral gavage (Naknukool
et al., 2011). Twenty-four hours after administration, the chemotactic activity of peritoneal
macrophages harvested from the mice was statistically significantly higher in all dosed animals
compared to control. The phagocytosis activity of peritoneal macrophages was statistically significantly
higher in all animals fed 0.5 or 5 mg Quillaia extract/kg compared to control. Chemotactic and
phagocytosis activity of macrophages harvested from mice after 1, 2, 4 and 10 days of 0.5 mg Quillaia
extract/kg was statistically significantly increased after day 1, 2 and 4, but not day 10.
Mice dosed with 0, 0.05, 0.5 or 5 mg Quillaia extract/kg were injected intraperitoneally 24 h later with
an E. coli suspension. The survival rate of mice infected with E. coli showed that average survival time was
3.8 days for the 0.5 mg Quillaia extract/kg treated group vs. 2.5 days for the control group (p < 0.05).
Human studies
In the study by Naknukool and co-workers, eight healthy male volunteers (22–23 years of age)
were given 0.5 mg Quillaia extract/kg bw per day in a drink for 7 days (Naknukool et al., 2011). Blood
was sampled before intake of the drink and 24 h after last administration of the drink. Blood samples
were analysed for macrophage activity, immunoglobulins E (IgE) and G (IgG), GOT, GPT, gamma-
glutamyl transferase, C-reactive protein, interleukin-1-alpha (IL-1a) and tumour necrosis factor alpha
(TNFa). The macrophages from the volunteers after Quillaia extract intake showed significantly
increased chemotactic (43.97.3 vs. 7.51.3 cells/area) and phagocytosis activity (64.07.2 vs.
24.54.5%) than before Quillaia extract intake (p < 0.05) (n = 6). Levels of a1- and a2-globulin were
elevated after Quillaia extract intake (p < 0.05) compared to before intake of Quillaia extract (n = 8).
No other effects were observed in blood samples from the human volunteers. The authors concluded
that Quillaia extract is a potent macrophage-stimulating agent that might be used to prevent
pathogenic infection in humans. The Panel noted that no control group was included in this study and
that reporting of results is biased because eight volunteers participated, whereas the results for
macrophages were reported only for six volunteers.
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Overall, the Panel noted that immunostimulatory effects of saponins from Quillaia extracts were
already used in different species in veterinary vaccines owing to their role as an adjuvant (Rajput
et al., 2007; Mendes et al., 2010; Ahlberg et al., 2017; Marciani, 2018). The mechanisms of action are
poorly understood and these observations could not be used for the assessment of the food additive
Quillaia extracts.
3.5.9. Studies with other emulsifiers
Quillaia extract (E 999) is described as an emulsifier and foaming agent (Documentation EFSA n. 6).
In several recent studies, some other emulsifiers have been reported to alter the gut microbiota, to
promote gut inflammation, obesity and to impair glycaemic control (Swidsinski et al., 2009a,b; Renz
et al., 2012; Merga et al., 2014; Cani and Everard, 2015; Chassaing et al., 2015; Romano-Keeler and
Weitkamp, 2015; Lecomte et al., 2016; Chassaing et al., 2017; Nejrup et al., 2017; Shah et al., 2017;
Jiang et al., 2018; Holder and Chassaing, 2018; Viennois and Chassaing, 2018). No such data are
available for Quillaia extract .
3.6. Discussion
According to Commission Regulation (EU) No 231/2012, Quillaia extract (E 999) is obtained by
aqueous extraction of Quillaia saponaria Molina, or other Quillaia species, trees of the family Rosaceae.
It contains a number of triterpenoid saponins consisting of glycosides of quillaic acid. Sugars –
including glucose, galactose, arabinose, xylose, and rhamnose – are also present, along with tannin,
calcium oxalate and other minor components.
The Panel noted that existing EU specifications for E 999 do not describe any range for saponins
content in the food additive. The JECFA specifications, however, differentiate two types of Quillaia
extracts, Type 1 and Type 2, containing a different percentage of saponins and other parameters. The
Panel considered that similar differentiation of the extracts of Quillaia should be presented in the EU
specifications as E 999(i) and E 999(ii) including the percentage range for saponins, polyphenols
(including tannins), protein, polysaccharides including fibre, reducing sugars, a maximum limit for
calcium oxalate as well as microbiological specifications.
The Panel assumed that the test materials used in toxicological studies described as Quillaia extract
approximated to Quillaia extract Type 1 as described in JECFA specifications (2006c). When available,
details on the extracts used in toxicological studies are provided in Appendices M and N. However,
from the information provided, the Panel could not ascertain the comparability of test materials
between different studies. The Panel noted that the material used in the toxicity studies may be
compliant with the current EU specifications; however, it is only poorly characterised.
The Panel considered that the extent and the quality of the available data on the ADME of Quillaia
extract saponins were very limited and that no conclusions could be drawn based on studies with
Quillaia extracts. The Panel, therefore, considered the available data on GI metabolism and ADME for
structurally similar saponins. Based on read-across from these data, the Panel assumed that Quillaia
extract saponins share a similar fate. Thus, the Panel considered it likely that intact Quillaia extract
saponins are absorbed to a low extent; are hydrolysed in the GI tract and that the aglycone is
absorbed only to a limited extent.
The CVMP of EMA (1996) noted that the inability of the haemolytic saponins to cross the gut
mucosa has been attributed to the ‘rapid elimination of permeabolised mucosal cells of the small
intestine by the normal process of epithelial replacement’, and the Committee suggested that ‘the low
oral toxicity of orally-administered saponins could then be explained by the large surface area of the
GI tract of mammals in relation to the concentration of saponins’.
The Panel considered that, from the limited data available, the acute toxicity for Quillaia extract
was low.
The Panel noted a NOAEL of 0.6% Quillaia extract (approximately 400 mg/kg bw per day) from a
13-week study in rats in which relative organ weights were changed at the next higher dose of
1,200 mg/kg bw per day (Gaunt et al., 1974). The Panel also noted that no histopathological changes
were observed at any dose.
The Panel considered that the data on the chemical composition of the mixture and the
genotoxicity data available did not indicate a concern for genotoxicity.
The Panel identified a NOAEL of 750 mg Quillaia extract/kg bw per day from a 84-week study in mice
and a NOAEL of 1,500 mg Quillaia extract/kg bw per day, the highest dose tested, from the 2-year study
in rats. There was no indication for carcinogenicity. In the mouse study, slightly lower body weight gain
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and some organ weight changes in the high-dose group of 2,250 mg/kg bw per day Quillaia extract were
reported but there were no histopatological changes.
No reproductive or developmental toxicity data were available to the Panel. However, in a chronic
study in rats, no adverse effects were observed in the reproductive organs.
The Panel considered the gut epithelium - as a site of contact – a potential target for any effects of
Quillaia extract. The Panel therefore focussed attention on any GI effects in the biological and
toxicological studies. The Panel considered that although exposure to Quillaia extract resulted in
changes in GI organ weights in several studies relevant to its use as a food additive, these changes
were not accompanied by any consistent treatment- and/or dose-related histopathological changes.
Taking into account the available toxicological database, the Panel noted that various NOAELs
relevant for the derivation of an ADI were identified:
• a NOAEL of 400 mg Quillaia extract/kg bw per day in a 13-week study in rats,
• a NOAEL of 750 mg Quillaia extract/kg bw per day in an 84-week study in mice,
• a NOAEL of 1,500 mg Quillaia extract/kg bw per day (the highest dose tested) in a 2-year
study in rats.
Overall, the Panel considered that the 2-year study in rats was the most robust and that the NOAEL
of 1,500 mg Quillaia extract/kg bw per day could be used to derive the ADI for Quillaia extract
(E 999). Considering that the adverse effects reported were due to the presence of saponins in the
extract, that saponins were present in Quillaia extract Type 1 at around 20% (conservative scenario
since Quillaia extract Type 1 may contain 20–26% of saponins) and using an uncertainty factor of 100,
the Panel derived a ADI of 3 mg saponins/kg bw per day for the food additive Quillaia extract (E 999).
Quillaia extract (E 999) is currently authorised in two food categories (Table 3). The extension of
use as a food additive in flavourings relates to five other food categories (Table 4). The exposure to
this additive was estimated based on MPLs and use levels, both for its current uses only and its current
uses and intended extension of uses, based on the proposed maximum levels in final foods by the
applicant (Section 3.4.1). As described in Section 3.4.1, overall the Panel estimated that the exposure
to Quillaia extract (E 999) was overestimated in all scenarios.
The Panel noted that MPLs are expressed as anhydrous extract in Annex II to Regulation No 1333/
2008. Therefore, exposure to Quillaia extract (E 999) was expressed in mg anhydrous extract of Quillaia
extracts (E 999)/kg bw per day. Considering that the ADI is expressed in mg saponins, exposure was
also converted to saponins, assuming that Quillaia extract (E 999) contains 70%15 saponins (Type 2) for
the current authorised use levels and as proposed by the applicant 20% saponins (Type 1) for the new
proposed uses. Therefore, exposure using the current MPLs (regulatory maximum level exposure
assessment scenario) ranged between < 0.1 mg saponins/kg bw per day at the mean up to 6.7 mg
saponins/kg bw per day at the 95th percentile. Using the refined exposure assessment scenario including
the proposed extension of use, exposure ranged between < 0.1 mg saponins/kg bw per day at the mean
up to 0.7 mg saponins/kg bw per day at the 95th percentile (Appendix O).
To assess possible health risks related to the current use of Quillaia extract (E 999), the
Panel selected the brand-loyal scenario as the additive is used in FC 14.1.4 Flavoured drinks. The
exposure estimates of the scenario based solely on MPLs were not used for this purpose as they were
recognised to be very conservative. None of the exposure estimates for the different population groups
of the brand-loyal scenario exceeded the ADI of 3 mg saponins/kg bw per day. Also the proposed
extension of use as a food additive in flavourings did not result in an exceedance of this ADI at the
refined exposure assessment scenario.
The Panel noted that the refined exposure estimates are based on information provided on the
reported level of use of Quillaia extract (E 999). If actual practice changes, this refined estimates may
no longer be representative and should be updated.
The applicant proposed the addition of sodium benzoate (E 211) to Annex III of Regulation (EC) No
1333/2008 as a preservative for use in liquid formulations of Quillaia extracts (E 999). The Panel noted
that exposure to sodium benzoate (E 212) at the levels proposed to be used in the preparation of
Quillaia extract (E 999) would add at the maximum 0.13% to the exposure to benzoic acid–benzoates
(E 210–213) as food additives, considering their use according to Annex II to Regulation No 1333/
2008 and additional exposure from food categories which may contain benzoic acid–benzoates due to
carry-over, for which an exceedance of the ADI of 5 mg/kg bw per day, expressed as benzoic acid,
was observed in the non-brand-loyal scenario for toddlers and children (EFSA ANS Panel, 2016).
15 From analytical data provided by interested parties (Documentation provided to EFSA n. 6)
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4. Conclusions
The Panel concluded that any toxicity associated with Quillaia extract (E 999) is due to its
constituent saponins and, therefore, an ADI based on saponins content can be derived. Accordingly,
the ADI for Quillaia extract (E 999) of 5 mg spray-dried extract/kg bw per day is withdrawn.
Taking into account the toxicological data available, the Panel established an ADI of 3 mg saponins/kg
bw per day for Quillaia extract (E 999) based on the NOAEL of 1,500 mg Quillaia extract/kg bw per day and
the conservative assumption that it contained 20% saponins, and by applying an uncertainty factor of 100.
The exposure estimates for the different population groups of the brand-loyal scenario did not
exceed the ADI of 3 mg saponins/kg bw per day at the reported use levels.
The Panel concluded that the proposed extension of use of Quillaia extract (E 999) as a food
additive in flavourings at the proposed uses and use levels would also not result in an exceedance of
the ADI at the refined exposure assessment scenario.
The proposed addition of sodium benzoate (E 211) to Annex III of Regulation (EC) No 1333/2008
as a preservative for use in liquid formulations of Quillaia extracts (E 999) at the proposed levels would
add at the maximum 0.13% to the exposure to benzoic acid–benzoates (E 210–213) as food additives
for which an exceedance of the ADI of 5 mg/kg bw per day, expressed as benzoic acid, was observed
in the non-brand-loyal scenario for toddlers and children (EFSA ANS Panel, 2016).
5. Recommendations
The Panel recommended that the European Commission considers:
• Revising the EU specifications for Quillaia extracts (E 999) in order to differentiate extracts of
Quillaia according to the saponins content (including a description of the principle of the
method of analysis to quantify the content of saponins in line with the JECFA specifications),
i.e. Type 1 and Type 2.
• Revising the EU specifications to include the percentage range for polyphenols (including
tannins), protein, polysaccharides including fibre, reducing sugars, a maximum limit for calcium
oxalate as well as microbiological specifications.
• Lowering the current limits for toxic elements (arsenic, lead and mercury) in the EU
specifications for Quillaia extracts (E 999) in order to ensure that the food additive will not be
a significant source of exposure to these toxic elements in food.
• Revising the maximum use levels for Quillaia extracts (E 999) established in Regulation (EC)
No 1333/2008 to be expressed on saponin content.
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism, excretion
ANS EFSA Panel on Food Additives and Nutrient Sources added to Food
AUC area under the plasma concentration-time curve
BMI body mass index
bw body weight
Cmax maximum concentration in plasma
CAS Chemical Abstracts Service
CMC critical micelle concentration
CONTAM EFSA Panel on Contaminants
CVMP Committee for Veterinary Medicinal Products
ECHA European Chemical Agency
EINECS European Inventory of Existing Commercial Chemical Substances
EMA/EMEA European Medicines Agency
FAF EFSA Panel on Food Additives and Flavourings
FC food category
FCS food categorisation system
FDE Food Drink Europe
FSANZ Food Standards Australia New Zealand
GI gastrointestinal
GLP good laboratory practice
GNPD Global New Products Database
GOT glutamic oxaloacetic transaminase




JECFA Joint FAO/WHO Expert Committee on Food Additives
LC–MS/MS liquid chromatography tandem mass spectrometry
LD50 lethal dose, median
LDH lactate dehydrogenase
LLOQ lower limit of quantification
LOD limit of detection
LOQ limit of quantification
MPL maximum permitted level
MRL maximum residue level
MRT mean residence time
MTD maximum tolerated dose level
NGFc Notoginsenoside Fc
NOAEL no observed adverse effect level




REACH Registration, Evaluation, Authorisation and Restriction of Chemicals
RET reticulocytes
RICC reduction in relative increase in cell count
RP-HPLC reverse-phase high performance liquid chromatography
SCF Scientific Committee on Food
SPF specific pathogen-free
t1/2 half-life
TemaNord is a publishing series for results of the often research-based work that working
groups or projects under Nordic Council of Ministers have put in motion
TNFa tumour necrosis factor alpha
UPLC-Q/TOF-MS ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry
WHO World Health Organization
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Appendix A – Specifications of the 1973 British Pharmacopoeia
The latest evaluation performed by the SCF (1978) was based on toxicological studies carried out
with a natural extract of Quillaia bark as specified in the 1973 edition of the British Pharmacopoeia, as
reproduced in Table 2.
Table A.1: Specifications for Quillaiæ cortex (Quillaia Bark) and Powdered Quillaia as reported in
British Pharmacopoeia (1973)
Quillaia Quillaiæ cortex; Quillaia Bark
Quillaia is the dried inner part of the bark of Quillaja saponaria Molina, and of other species of Quillaja
Description: Odourless; dust strongly sternutatory; taste, acrid and astringent
Macroscopical Pieces flat, up to about 1 metre long, 10–20 cm broad and 3 to 6 to 10 mm thick.
Outer surface brownish-white or pale reddish-brown, longitudinally striated or
coarsely reticulated, with occasional black-brown patches of adherent outer bark;
inner surface yellowish-white, smooth and very hard; fracture splintery and
laminated, the broken surface showing numerous large prisms of calcium oxalate as
glistening points. Smoothed transversely cut surface appearing chequered, with
delicate radial lines representing medullary rays and tangential lines formed by
alternating tangential bands of fibrous and non-fibrous phloem containing fibres
Microscopical. Outer bark, when present, consisting of reddish-brown cork cells alternating with
bands of brown parenchyma containing numerous groups of phloem fibres and large
prisms of calcium oxalate. Inner bark consisting of alternating bands of tortuous
fibres irregularly enlarged at intervals about 500 to 1,000 lm long and 20 to 50 lm
wide and of mixed sieve tissue with parenchyma. Medullary rays mostly 3 to 4, but
sometimes up to 6 cells wide, with occasional pitted, subrectangular sclereids
adjacent to the bundles of phloem fibres. Starch grains 5 to 10 to 20 lm in diameter,
and prisms of calcium oxalate usually 50 to 170 lm long and up to 30 lm wide
present in the parenchymatous cells
Acid-insoluble ash Not more than 1.0%, page A88
Alcohol (45%)-soluble
extractive
Not less than 22.0%, page A89
Foreign organic matter Not more than 2.0%, page A99
Powdered Quillaia
Complies with the requirements for Acid-insoluble ash, Alcohol (45%)-soluble extractive, and Foreign organic
matter stated under Quillaia and with the following requirement
Description: Pale buff with a pink tinge. Diagnostic structures: phloem fibres, in bundles;
occasional sclereids; calcium oxalate prisms, often in fragments; starch grains and
cork cells in small amount. When shaken with water a copious persistent froth is
produced
Action and use Emulsifying agent
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Appendix B – Summary of reported use levels (mg/kg or mg/L as
appropriate) of Quillaia extracts (E 999) provided by industry
Appendix C – Number and percentage of food products labelled with
Quillaia extracts (E 999) out of the total number of food products present
in the Mintel GNPD per food subcategory between 2013 and 2018
Appendix D – Concentration levels of Quillaia extracts (E 999) used in the
exposure assessment scenarios (mg/kg or mL/kg as appropriate)
Appendix E – Concentration levels of Quillaia extracts (E 999) used in the
exposure assessment scenarios including the extensions of use (mg/kg or
mL/kg as appropriate)
Appendix F – Summary of total estimated exposure of Quillaia extracts
(E 999) from its use as a food additive for the regulatory maximum level
exposure scenario and the refined exposure assessment scenarios per
population group and survey: mean and 95th percentile (mg/kg bw per
day)
Appendix G – Main food categories contributing to exposure to Quillaia
extracts (E 999) using the regulatory maximum level exposure assessment
scenario and the refined exposure assessment scenarios (> 5% to the total
mean exposure)
Appendix H – Summary of total estimated exposure of Quillaia extracts
(E 999) from its use as a food additive including the proposed extensions
of use, for the regulatory maximum level exposure scenario and the
maximum exposure assessment scenarios per population group and
survey: mean and 95th percentile (mg/kg bw per day)
Appendix I – Main food categories contributing to exposure to Quillaia
extracts (E 999) from its use as a food additive including the proposed
extensions of use, for the regulatory maximum level exposure scenario
and the maximum exposure assessment scenarios per population group
and survey: mean and 95th percentile (mg/kg bw per day)
Appendicies B–I can be found in the online version of this output (‘Supporting information’ section)
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Appendix J – Identity of the substances proposed for read-across for ADME
data; gastrointestinal metabolism
Data from other saponins, structurally related to Quillaia saponins, have been used for the
assessment.
A number of other triterpenoid saponins have an aglycone backbone similar to quillaic acid: for the
purpose of this opinion, read-across from saponins – having oleanolic acid instead of quillaic acid (see
Figure J.1) – was considered relevant for ADME data (Table J.1).
Other saponins (i.e. gingseng saponins, soybean saponins) were also considered relevant for the
read-across on ADME data due to the fact that they bear side chain attachments similar to the quillaia
saponins, despite having a 4-ring backbone structure instead of a 5-ring structure.
Figure J.1: Structural formula of oleanolic acid
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Table J.1: Saponins considered for read-across
Name Botanical source Structure
Glycyrrhizin Liquorice
b-Aescin (b-escin) Aesculus hippocastanum
Pulsatilla saponin D Pulsatilla chinensis
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Name Botanical source Structure
DS-1 Dianthus superbus
Anhuienoside C Anhemone flaccida Fr. Schmidt (rhizome)
(traditional Chinese medicine ‘Di Wu’)
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Name Botanical source Structure
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Name Botanical source Structure
Hederacolchiside E Pulsatilla koreana
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Appendix K – Gastrointestinal metabolism of saponins
In silico
The apical to basal permeability coefficient (Papp,A-B) of anhuienoside C was reported to be
3.04 9 10-6 cm/s (Volpe, 2011). This value was below the threshold value for poorly absorbed drugs
(1 9 10-5 cm/s) (Rubas et al., 1993) and thus indicative of a poorly absorbed compound (Varma et al.,
2012).
In vitro studies
Gutierrez and Davis (1962) isolated colonies of saponins-digesting bacteria from the rumen fluid
obtained from yearling steers that were permitted to graze on lush, pre-bloom Ladino clover (Trifolium
repens) for two, one and a half-hour period and also experienced bloating. The authors quantified the
amount of ‘slime’ harvested from inoculations of the bacteria, 0.5% yeast extract, 0.5% trypticase
broth, and 2 g of alfalfa saponins after a 24-h incubation period. The ‘slime harvest’ ranged from
0.146 to 0.884 g (compared to 0.080 g for an uninoculated control), and analysis revealed that the
slime was primarily composed of residual sapogenins.
The CVMP of the EMA (formerly EMEA) noted that hydrolysis of saponins to sapogenins and sugars
has been demonstrated in vitro (EMA, 1996). Although no study details were provided, two
publications (Gutierrez and Davis, 1962; Gestetner et al., 1968) were cited in the Maximum Residue
Limit Expert Report submitted to the EMEA for Quillaia saponins.
Okamura et al. (2003) incubated glycyrrhizin with fresh faeces from male Wistar rats and reported
that the primary metabolite retrieved was glycyrrhetic acid. In addition, trace amounts of 3-a-
hydroxyglycyrrhetic acid and 3-dehydroglycyrrhetic acid were formed when incubated under anaerobic
conditions while under aerobic conditions, increasing amounts of 3-dehydroglycyrrhetic acid were
produced over the 48-h incubation period.
Kim et al. (1999, 2000) isolated microbial glucuronidases from various intestinal bacteria and
demonstrated that some glucuronidases remove both glucuronide moieties from glycyrrhizin, while
others remove only one. Data from other in vitro studies also indicate that human intestinal bacteria
isolated from faeces are capable of metabolising glycyrrhizinic acid to glycyrrhetic acid, as well as to 3-
epi-glycyrrhetic acid and 3-dehydroglycyrrhetic acid (Hattori et al., 1983). In the same study, it was
also demonstrated that human intestinal bacteria can metabolise glycyrrhetic acid to 3-epi-glycyrrhetic
acid and the parent compound. A ‘fair number’ of bacteria from the human gastrointestinal flora were
reported to have b-glucuronidase activity, and thus, the capability of metabolising glycyrrhizinic acid to
glycyrrhetic acid (Hattori et al., 1985). A fewer number of bacteria were capable of reducing 3-
dehydroglycyrrhizinic acid to glycyrrhizinic acid or 3-epi-glycyrrhizinic acid.
Escin Ia also is reported to be extensively metabolised by the intestinal microbiota and specifically
by Lactobacillus brevis (Yang et al., 2004).
Anhuienoside C, a triterpenoid saponin from the rhizome of Anemone flaccida Fr. Schmidt (known
as ‘Di Wu’ in Chinese), was demonstrated to be stable in fasted state simulating gastric fluid for at
least 3 h and was sequentially deglycosylated into 4 metabolites by the intestinal microflora from male
Sprague–Dawley rats (Zhao et al., 2015). The structures of the metabolites were determined using
ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF-
MS) and confirmed using nuclear magnetic resonance spectroscopy. The final metabolite was the
aglycone oleanolic acid, whose structure also was confirmed using its reference standard. According to
the authors, oral bioavailability of anhuienoside C was primarily limited by its bacterial metabolism.
Deglycosylation and oxygenation were considered primary and secondary metabolic pathways,
respectively (Hasegawa, 2004; Qian and Cai, 2010; Wang et al., 2011). In the deglycosylation
reactions, intestinal bacteria cleave the oligosaccharides connected to the C-3 or C-20 hydroxyl group
of the aglycone in a step-wise manner from the terminal sugar. Using an UPLC-Q/TOF-MS technique,
notoginsenoside Fc (NGFc), a protopanaxadiol (PPD)-Type saponin, was proposed to go through a
series of deglycosylation reactions, forming eight metabolites, which were identified in the faeces of
male Sprague–Dawley rats following a single oral dose of 100 mg/kg (He et al., 2015).
Human gastrointestinal microflora also is capable of metabolising the ginsenosides (Yu et al., 2012).
In vitro studies indicated that the sugar side chains from ginsenosides Rb1, Rb2, Rc, Rd, Re and Rg1
were removed following anaerobic incubation with human fecal microflora. Incubation of American
ginseng (Panax quinquefolius L.) root extract with human intestinal microflora obtained from the fresh
faeces of a healthy male resulted in the identification of 25 metabolites that were either not detected
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or present only in trace amounts in the original extract (Wan et al., 2013). Major metabolic pathways
of the PPD and protopanaxatriol (PPT) ginsenosides included the removal of C-3 sugar moieties,
removal of the C-20 sugar moieties, and dehydration, while the major metabolic pathways of the
minor oleanane ginseng saponins were removal of sugar moieties from the C-3 and/or C-28 positions.
Thus, deglycosylation by sequential cleavage of the sugar moieties was the primary metabolic pathway
of saponins from American ginseng extract.
To elucidate further the metabolism of saponins in the digestive tract, Gestetner et al. (1968)
excised the small intestine, cecum and colon of rats, mice and chicks that had been fed a standard
diet lacking soybean flour for 14 days and incubated the various sections with soybean saponins
extract at the corresponding pH levels for 3 h at 37°C. Chromatographic analysis of the digests
indicated that only saponins were present in the small intestine, whereas both saponins and
sapogenins were present in the cecum and colon. As summarised above, Gestetner et al. (1968) then
demonstrated that the microorganisms from the cecum and colon were responsible for the metabolism
of saponins to sapogenins and suggested that the enzyme responsible was a glycosidase(s) with a low
degree of specificity due to the liberation of several sugars from soybean and alfalfa saponins.
In vivo studies
Glycirrhizin was metabolised to glycyrrhetic acid by the gastrointestinal microflora through the
removal of the two molecules of glucuronic acid attached at carbon 3 following the oral administration
of 10 mg/kg bw glycyrrhizin (i.e. glycyrrhizinic acid) to male Wistar and Sprague–Dawley rats (Takeda
et al., 1996).
The low bioavailability of escin saponins was suggested by Wu et al. (2012) to be caused by first-
pass metabolism in the gastrointestinal tract.
Ginseng contains a complex mixture of ginsenosides, with greater than 150 ginsenosides having
been identified in various Panax species (Yu et al., 2012). Among these, the PPD-Type ginsenosides
Rb1, Rb2, Rc and Rd and the PPT-type ginsenosides Re and Rg1 comprise greater than 90% of the
total ginsenoside content. Ginseng ginsenosides are metabolised extensively in the gastrointestinal
tract of animals and humans by the intestinal microflora following oral administration (Hasegawa,
2004; Qi et al., 2011; Wang et al., 2011; Yu et al., 2012; Wan et al., 2013).
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Appendix L – ADME of related saponins
In vivo studies
In the Gestetner et al. (1968) study, groups of 10 male albino mice, 3 male rats and 3 male
Leghorn chicks were fed diets comprising 20% heated soybean flour for 10 days, and their digestive
tracts were excised for the determination of soybean saponin and sapogenin contents. Soybean
saponins were detected (detection limit 40 lg) in the small intestine, but not in the caecum, colon, or
blood of the mice, rats, and chicks that had consumed diets comprising 20% heated soybean flour for
10 days. Sapogenins (LOD 4 lg) were detected in the caecum and colon, but not in the small intestine
or blood. The lack of detection of saponins and sapogenins in the blood indicates that neither the soya
bean saponins nor their hydrolysis products were absorbed from the digestive tract of mice, rats, or
chicks, within the LODs. The authors noted that the lack of detection of saponins in the cecum or
colon did not necessarily indicate that they were fully metabolised to sapogenins, as they may have
still been present but below the limit of detection due to their initially low concentration.
Yoshikoshi et al. (1995) came to a similar conclusion, as neither saponins nor their aglycones were
detected in the blood (detection limit 0.01 lM) of Wistar rats that had consumed a diet containing
10% soybean hypocotyls for 2 weeks. Although not quantified, low levels of soybean saponins and
greater levels of their aglycones were detected in faeces using thin layer chromatography. The authors
suggested that these results indicated that the majority of soybean saponins were hydrolysed to their
aglycones in the gastrointestinal tract.
The oral bioavailability of the escin saponins, glycyrrhizin, pulsatilla saponin D and DS-1 from
Dianthus superbus has been investigated in rats (Wang et al., 1995; Wu et al., 2012; 2014; Ren et al.,
2017; Ouyang et al., 2015). The escin saponins had oral bioavailabilities ranging from 0.16% to 1.97%
of the administered dose (Wu et al., 2012, 2014). The oral bioavailability of glycyrrhizin following oral
administration of a glycyrrhiza extract was 1.7%, whereas the oral bioavailability of glycyrrhizin
following administration of the pure saponins was 4.0% (Wang et al., 1995). Thus, the bioavailability
of glycyrrhizin was less when consumed as a complex mixture (i.e. the extract) than when consumed
as a purified compound. The oral bioavailability of pulsatilla saponin D was slightly higher, at 2.83%
(Ouyang et al., 2015), whereas the oral bioavailability of DS-1 was quite low, at 0.92% (Ren et al.,
2014). Ren et al. (2014) suggested that the low oral bioavailability of DS-1 may be due to its large
molecular mass, high hydrogen-bonding capacity, and poor water solubility.
Pharmacokinetic parameters were also investigated for asperosaponin VI, BTS-1 and hederacolchiside
E (Yoo et al., 2008; Li et al., 2010; Luo et al., 2013). Although the oral bioavailabilities were not
determined, the area under the plasma concentration–time curve (AUC) values were quite low, ranging
from 0.56 to 138.3 lg*h/mL, and thus, it is expected that their corresponding oral bioavailabilities also
will be low. Double peaks were observed in the plasma-concentration time curves for asperosaponin VI,
which suggested that it may undergo enterohepatic recirculation (Li et al., 2010).
The pharmacokinetics of escin saponins were investigated in a single study involving 10 healthy
male volunteers (Wu et al., 2010). Although the bioavailability of the isomers was not determined, the
AUC values were low, ranging from 1.8 to 22.4 ng*h/mL, which suggests that the escin saponins have
low oral bioavailability in humans. Similar to what was observed in rats, multiple peaks were observed
in the AUC for the escin saponins in some subjects, suggesting that either tissue redistribution or
enterohepatic recycling was occurring. A summary of the pharmacokinetic data from this study is
presented in Table L.1.
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Escin Ia 10 healthy males
(20–30 years old;
BMI = 20–24)





Wu et al. (2010)
Escin Ib 11.4 0.38  0.26 4.7  3.0 NR 2,900  1,360 1.8  0.9 ND
Isoescin Ia 16.8 1.82  1.60 13.7  3.8 NR 964  426 22.4  13.6 ND
Isoescin Ib 7.2 0.74  0.73 8.4  2.5 NR 3,890  1,940 5.8  3.8 ND
BMI: body mass index; Cmax: maximum concentration in plasma; LC–MS/MS: liquid chromatography tandem mass spectrometry; LLOQ: lower limit of quantification; MRT: mean residence time; ND:
not determined; NR: not reported; t1/2: half-life; AUC: area under the plasma concentration–time curve.
(a): From 60 mg total escins.
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Appendix M – Characterisation of the test material used in toxicological
studies evaluated by the SCF and JECFA
The current ADI of 5 mg/kg bw per day (expressed as dry extract 15% w/w) was set by the SCF in
1978 on the basis of two long-term studies in rats and mice.
The study in mice Butterworth (1977a, as referred to by the SCF (1978)) was later published by
Phillips et al. (1979). The study in rats Butterworth (1977b, as referred to by the SCF (1978)) was
later published as Drake et al. (1982).
Test material from the same supplier was possibly used also by Gaunt et al. (1974) in a short-term
toxicity study in rats.
The characteristics of the test material used in these three studies, as described in the publications,
are reported in Table M.1.
Table M.1: Description of the test material used in the toxicological studies by Gaunt et al. (1974),
Phillips et al. (1979) and Drake et al. (1982)
Gaunt et al. (1974)
Phillips et al. (1979; cited
by SCF as Butterworth,
unpublished, 1977a)




extract prepared in such a
way that 100 parts by
weight of bark yielded
approximately 15 parts of
extract. In addition, the
sample contained 5%
lactose added to the
extract before drying
Spray-dried aqueous extract
prepared in such a manner that
100 parts by weight of bark
yielded approximately 15 parts
of extract before drying
Spray-dried aqueous extract
prepared in such a way that 100
parts by weight of bark yielded
approximately 15–18 parts of
powdered extract







Moisture: Less than 10% Less than 10% Less than 10%
Ash (at 550°C): Less than 10% Less than 10% Less than 10%
Conformity: Not stated; however,
JECFA (2002b) considered
the extract to meet
specifications for Quillaia
extract according to the
Emulsifiers and Stabilisers
in Food Regulation 1975
Requirements of The Emulsifiers
and Stabilizers in Food
Regulation 1975 (Statutory
Instrument 1975, 1486)
UK Emulsifiers and Stabilisers in
Food Regulation 1975 (Statutory
Instrument 1975, no. 1486) and
to that in the British
Pharmacopoea (1973)
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Appendix N – Characterisation of the test material used in the newly
generated genotoxicity tests
Upon request from EFSA, additional studies performed in accordance with the EFSA SC opinion on
genotoxicity testing strategies (EFSA Scientific Committee, 2011) were submitted to EFSA for
evaluation (See Section 3.5.4).
The material used for these studies was characterised as presented in Table N.1.
Table N.1: Description of the test material used in the genotoxicity tests submitted in response to a
request from EFSA (Documentation provided to EFSA n. 8)
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Appendix O – Summary of anticipated exposure to Quillaia extract (E 999)
from its use as a food additive in the regulatory maximum level exposure
assessment scenario for the current authorised uses and in the refined
exposure scenario including the proposed extension of use, in six
population groups (minimum–maximum across the dietary surveys


















Regulatory maximum level exposure assessment scenario
 Mean 0–0.4 0–1.9 0.1–2.1 0.2–1.6 0.1–0.7 < 0.1–0.2
 High level
(95th percentile)
0–2.2 0–6.7 0.7–5.3 0.8–3.7 0.4–2.4 0.1–0.8
Refined exposure assessment scenario + proposed extension of use
 Mean < 0.1–< 0.1 < 0.1–0.2 < 0.1–0.2 < 0.1–0.2 < 0.1–0.1 < 0.1–< 0.1
 High level
(95th percentile)
0–0.2 < 0.1–0.7 0.1–0.5 0.1–0.4 < 0.1–0.3 < 0.1–0.2
bw: body weight.
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